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1 Introduction 
 
 
1.1 Haemostasis 
 
 
Haemostasis begins at the site of injury and is accomplished through blood coagulation. 
When dealing with patients with an increased bleeding tendency, the understanding of 
this mechanism is of crucial importance. It was Morawitz who first presented a simple 
two step-four factor model in the early 1900´s, according to which prothrombin is con-
verted to thrombin (activated by FIII and FIV), and then fibrinogen transforms to fibrin, 
activated by the previously formed thrombin (Morawitz, 1905).   
In the years that followed, a number of coagulation factors were discovered by several 
different groups which coined different terms, thereby causing great misunderstanding. 
In 1954, with the formation of the „„International Committee on Nomenclature of Blood 
Clotting Factors‟‟, however, a common nomenclature was established (Monroe et al, 
2007). This allowed short after, in 1964, the developing of the waterfall/cascade model 
of coagulation (Macfarlane, 1964, Davie, Ratnoff, 1964).  
The basic principle of the coagulation waterfall/cascade suggests that the various clot-
ting factors are converted, in succession, to active enzymes until the final substrate, fi-
brinogen. Thrombin then converts fibrinogen to fibrin (Davie, Ratnoff, 1964). More 
specifically, the coagulation waterfall/cascade model consists of the extrinsic and intrin-
sic pathways (Fig. 1), which are clinically assayed using the prothrombin time-
international normalised ratio (PT-INR) and the activated partial prothrombin time 
(aPTT) respectively (Hoffman, Monroe 2007).  However, the use of these screening 
tests to predict clinical bleeding is to be questioned.  Deficiencies of factor XII or XI, 
although they hold a high position in the intrinsic pathway of the cascade, might or 
might not be associated with significant haemorrhage. On the other side, deficiencies of 
factors VIII and IX, although lower in the same pathway, are consistently associated 
with haemorrhage. In spite of the dramatically different risk of haemorrhage, the defi-
ciency of all four factors can equally prolong the aPTT (Hoffman, Monroe, 2007).  As 
the extrinsic and intrinsic pathways are actually interdependent in vivo, the commonly 
used laboratory screening tests do not accurately reflect the complexity of haemostasis 
in vivo (Romney, Glick, 2009).  
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Intrinsic pathway                                                     Extrinsic pathway 
 
XII                 XIIa 
                            HMK,PK 
                XI                  XIa 
 
                              IX                 IXa                VIIa                  VII               
                                                       VIIIa                  TF 
                                          X                  Xa                  X 
                                                           Va 
                        II (prothrombin)                             IIa ( thrombin) 
 
                                                         fibrinogen                                     fibrin 
HMK: high molecular weight kininogen, PK: prekallikrein, TF: tissue factor  
 
Figure 1.  The coagulation waterfall/cascade 
 
Indeed, in 1977 it was observed that the reaction product of tissue factor (TF) and factor 
VII activates not only factor X of the extrinsic pathway but also factor IX of the intrin-
sic (Østerud, Rapaport, 1977). In addition, thrombin could activate factor XI on acti-
vated platelets in the absence of factor XII, suggesting that factors XII, high molecular 
weight kininogen (HMK) and prekallikrein (PK) might be of no use for the activation of 
factor XI and therefore for haemostasis (Oliver et al, 1999). Those two findings led to a 
concept of haemostasis in which tissue factor (TF) is the primary physiologic activator 
(cell-based model). 
The cell-based model of haemostasis suggests that different cell surfaces have very dif-
ferent properties regarding the coagulation process despite the similar membrane lipid 
composition. Indeed, the variety of cell features, including protein receptors, is respon-
sible for localising the different components of the coagulation mechanism and, ulti-
mately, for regulating it (Hoffman, Monroe, 2001). Hoffmann and Monroe argue that 
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haemostasis occurs in three overlapping phases, suggesting initiation, amplification and 
propagation. According to the cell-based model of coagulation, initiation occurs on the 
TF bearing cell where activated factor X (Xa) combines with activated factor V (Va) to 
activate small amounts of thrombin (initiation). This small amount of thrombin ampli-
fies the procoagulant response by activating cofactors, factor XI and platelets (amplifi-
cation). The large burst of thrombin is formed on the platelet surface (propagation) 
(Figure 2). 
 
Intrinsic pathway                                                     Extrinsic pathway 
 
XII                 XIIa 
                            HMK,PK 
                XI                  XIa          
                                                       amplification on TF-baring cells 
                              IX                 IXa                VIIa                  VII          propa-     
                                                       VIIIa                  TF                                      gation  
                                         X                  Xa                  X                          
                                                           Va                                                       initiation   
                        II (prothrombin)                             IIa ( thrombin)           
                                                                                                                 
                                                         fibrinogen                                     fibrin 
 
HMK: high molecular weight kininogen, PK: prekallikrein, TF: tissue factor 
amplification takes place on TF-baring cells, propagation on platelet surface and initiation on TF-
bearing cells 
 
 
Figure 2. The coagulation waterfall/cascade adjusted to the cell-based model 
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1.1.1 Haemostasis and liver function 
 
Haemostasis is closely related to liver function. Liver parenchymal cells synthesize 
most coagulation factors. Coagulation factors synthesized by the liver are fibrinogen, 
factor II, V, VII, VIII, IX, X, XI, XII, XIII, prekallikrein and high molecular weight 
kininogen. Liver malfunction also affects fibrinolytic system and platelet function as 
plasminogen and thrombopoietin are also synthesized by the liver (Wada et al, 2008).  
Thus, the degree of liver malfunction determines the extent of haemostatic disorders. 
Acute or chronic hepatocellular diseases may cause decrease in the Vitamin K depend-
ing factors while the level of other parameters remain normal. Vitamin K dependent 
procoagulants and coagulants is factor II, VII, IX, X and protein C and S.  A hepatic 
failure may result in factor deficiency of the entire spectrum and even in disseminated 
intravascular coagulation (DIC) (Mammen EF, 1992). 
 
 
Picture 1. Extended haematoma after multiple teeth extractions in patient with severe 
hepatopathy 
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1.2 Bleeding disorders 
  
A variety of clinical symptoms, including easy bruising, skin bleeding, mucosal and 
musculoskeletal bleeding and excessive blood loss after trauma or surgery, can be asso-
ciated with bleeding disorders, often underlying but undiagnosed. A detailed medical 
history and physical examination are important when treating a patient. A history of 
easy or spontaneous bruising, especially the size of more than 2-3 cm or in unusual 
sites, is a sign of alert. Epistaxis occurring more frequently with age rather than resolv-
ing or requiring medical intervention in the absence of a local anatomic abnormality 
implies an underlying bleeding disorder. In the absence of poor dental hygiene, sponta-
neous gingival bleeding is seen in primary haemostatic disorders, especially thrombocy-
topenia. Excessive bleeding at the time of dental extraction, surgery or trauma suggests 
inherited or acquired bleeding disorder. The patients often experience their first haemo-
static challenge after the loss of deciduous teeth and dental extractions. The severity and 
duration of the bleeding after dental extraction as well as the postoperative measures 
that were taken should be assessed. The appropriate laboratory investigations will con-
tribute to making the final diagnosis. In the tables that follow congenital and acquired 
bleeding disorders as well as causes of congenital and acquired thrombocytopenia are 
listed (White, Ryan, 2005, chap.3) (Tables 1,2). 
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     Congenital bleeding disorders                           Acquired bleeding disorders 
      
     Autosomal dominant disorders                               As a result of anticoagulation therapy                        
      Von Willebrand Disease                                        Hepatopathy   
      May-Hegglin anomaly                                            Disseminated intravascular coagulation  
                                                                                    Vitamin K deficiency                                                                             
      Autosomal recessive disorders                             Acute or chronic Leukemia                    
      Bernard-Soulier syndrome                                      
      Glanzmann’s thrombasthenia                               
      Gary platelet syndrome 
      Deficiencies of factors V, VII, X, XI, XIII 
      Type 3 von Willebrand Disease 
                                             
       
      Sex linked recessive disorders 
      Factor VIII deficiency 
      Factor IX deficiency 
      Wiskott-Aldrich syndrome                            
 
Table 1. Congenital and acquired bleeding disorders (White, Ryan, 2005, chap.3)  
 
 
Congenital thrombocytopenia                           Acquired thrombocytopenia 
 Inherited thrombocytopenia                                Decreased production       
 Bernard-Soulier syndrome                                  Bone marrow failure or infiltration 
 Wiskott-Aldrich syndrome                                   Megaloblastic Anaemia 
 May-Hegglin anomaly 
 Von Willebrand´s disease                                   Decreased lifespan 
 Gray platelet syndrome                                       Idiopathic autoimmune thrombocytopenia 
 Alport syndrome                                                  Drug induced thrombocytopenia 
                                                                             Autoimmune disease, Infections, including HIV 
                                                                             Post transfusion 
                                                                             Microangiopathic Anaemia 
                                                                               
                                                                             Hypersplenism                                                                                 
                          
Table 2. Causes of congenital and acquired thrombocytopenia (White, Ryan, 2005, 
chap.3) 
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Picture 2. Excessive haematoma after multiple extractions in patient with thrombocyto-
penia 
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1.3 Deficiency of coagulation factors  
 
1.3.1 Haemophilias  
 
Haemophilias are hereditary bleeding disorders associated with deficiency in a coagula-
tion factor. Haemophilia A involves deficiency of factor VIII (antihaemophilic factor) 
while Haemophilia B involves deficiency of factor IX (Christmas factor). They are both 
X-linked recessive diseases recognized almost exclusively in male hemizygotes (Arun, 
Kessler, 2001). In all ethnic groups, 1 in 10 000 males are affected by haemophilia 
while the prevalence of Haemophilia B is 20 % that of Haemophilia A (Giangrade, 
2005).  
The degree of the disease‟s severity is defined by the levels of factor activity and char-
acterizes the clinical spectrum of bleeding. Factors VIII and IX activity levels are ex-
pressed in units per millilitre (U per mL) or as a percentage of the activity determined in 
normal pooled plasma with 1 U per mL corresponding to 100% of the factor activity 
found in 1 mL of pooled normal plasma. Normal plasma activity levels range from 0,5 
to 1,5 U per mL (50% to 100%). Severe haemophilia is defined by factor activity levels 
less than 0,01 U per mL (less than 1%), moderately severe haemophilia by 0,02 to 0,05 
U per mL (2%-5%) and mild haemophilia by greater than 0,05 U per mL (>5%) (Gian-
grande, 2005).  
Severe haemophilia is characterized by recurrent and intense haemorrhage, occurring 
after a surgical operation but also after a minor trauma or even spontaneously. In child-
hood, lip or tongue biting as well as the loss of deciduous teeth are accompanied with 
intense oral bleeding. Large haematomas may also follow deep intramuscular injections 
or simple vaccination. In case of moderate haemophilia, bleeding is associated with sur-
gical or minor traumas. Mild haemophilia presents significant bleeding after major 
trauma or surgery. These patients are more often for the first time diagnosed before 
elective surgery when routine screening tests reveal prolonged activated partial throm-
boplastin time (Arun, Kessler, 2001).   
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Recombinant factor VIII is the therapy of choice for haemophilia A and recombinant 
factor IX for Haemophilia B (Keeling et al, 2008).  
Other therapeutic choices are antifibrinolytic agents, like tranexamic acid and desmo-
pressin (DDACVP). Tranexamic acid inhibits fibrinolysis by reversibly binding both 
circulating and fibrin-bound plasminogen. It is especially effective in mucosal bleeding 
where fibrinolytic activity is specially active. Ways of administration are orally, intra-
venously or as a mouth wash. Its combination with desmopressin provides prophylaxis 
for dental surgery (Keeling et al, 2008). Desmopressin (1-deamino-8-D-arginine vaso-
pressin, also known as DDAVP) can be the therapy of choice in cases of mild haemo-
philia A as it boosts the plasma levels of factor VIII after administration (Meili, Brand 
2006). Typically FVIII levels will increase 3-5 times above basal levels. It may be ad-
ministrated as a slow intravenous infusion or as a subcutaneous injection (Keeling at al, 
2008). When referring to antifibrinolytic therapy, it should be taken into consideration 
that factor IX concentrates fall into two classes, pure coagulation FIX products and 
prothrombin complex concentrates (PCCs). Purified FIX products are largely free of the 
risk of developing thrombosis or disseminated intravascular coagulation (DIC), which 
may occur with large doses of intermediate purity PCCs. Thus, antifibrinolytic agents 
either as primary or adjunctive therapy, are not recommended for treatment of patients 
with factor IX deficiency already receiving large doses of PCC (World Federation of 
Hemophilia, 2005).   
 
1.3.2. Von Willebrand disease 
 
Von Willebrand factor (vWF) is a plasma protein that mediates platelet haemostatic 
function and stabilizes blood coagulation factor VIII. Von Willebrand disease (vWD) is 
caused by deficiency or dysfunction of vWF (Nichols et al, 2008). Therefore, quantita-
tively or qualitatively abnormal von Willebrand factor can lead to bleeding by impairing 
platelet adhesion or by reducing the concentration of FVIII. 
The prevalence of the disease ranges from 0,0023-0,1% depending on the case defini-
tion that is used (Nichols et al, 2008). 
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The first patient reported was a five-year-old girl who was examined by Dr. Eric von 
Willebrand at the Deaconess Hospital of Helsinki in 1924. He first described this disor-
der as „‟hereditary pseudohaemophilia‟‟ (Von Willebrand, 1999). 
VWD is classified into three major categories: partial quantitative deficiency (type 1), 
qualitative deficiency (type 2) and total deficiency (type 3). Type 2 vWD is divided 
further into four variants (2A, 2B, 2M and 2N) on the basis of details of the phenotype.  
Type 1 is inherited as an autosomal dominant trait, its prevalence reaches 1% and the 
bleeding tendency is mild to moderate.  
Type 2A and 2M are inherited as an autosomal dominant or recessive trait while their 
prevalence is uncommon and their bleeding severity varies leaning to moderate.  
Type 2B is likewise uncommon with variable, mostly moderate bleeding tendency but is 
inherited only as an autosomal dominant trait. 
Type 2N is inherited as autosomal recessive trait and presents similarly uncommon 
prevalence and variable, mostly moderate bleeding propensity. 
Type 3 is the severe one with a high bleeding propensity although rare (1: 250 0000- 1: 
1 000 000). It is inherited as an autosomal recessive trait (Federici, 2008). 
 
Common bleeding symptoms of patients with von Willebrand disease are epistaxis, me-
norrhagia, ecchymoses, bleeding after dental extractions or operations, gingival bleed-
ing, bleeding from minor cuts or abrasions, gastrointestinal bleeding, heamarthrosis and 
postoperative bleeding (Nichols et al, 2008). 
Patients with the above mentioned clinical symptoms but with a negative past personal 
history and family history should be investigated for the presence of acquired von 
Willebrand disease (AvWD). AvWD may occur spontaneously associated with other 
diseases, such as monoclonal gammopathies, other plasma cell dyscrasias, lymphopro-
liferative diseases, myeloproliferative disorders (e.g. essential thrombocythemia), auto-
immune disorders, valvular and congenital heart disease, certain tumours and hypothy-
roidism (Nichols et al, 2008). 
Treating vWD aims at correcting the dual defects of haemostasis; abnormal platelet ad-
hesion as a result of low or defective vW factor and abnormal intrinsic coagulation as a 
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result of low factor VIII (Federici, 2008). This can be done using three therapeutic 
strategies which are not mutually exclusive and patients can receive one or all of them. 
The first approach uses desmopressin in order to stimulate endothelial cells to release 
endogenous vW factor. The second replaces vW factor by using human plasma-derived 
concentrates. The third approach aims at promoting haemostasis and wound healing 
without substantially altering the plasma concentration of vW factor. In case of dental 
surgery tranexamic acid as well as topical thrombin, collagen or fibrin sealant is used at 
the site of surgery (Nichols et al, 2008).           
              
1.3.3 Other factor deficiencies 
 
Factor XI deficiency is mostly diagnosed in Ashkenazi Jews but is also observed in 
other ethnic groups. Deficiency of factor XI is often described as Haemophilia C but the 
bleeding phenotype is much more variable than that of the haemophilias A and B. It is 
often the case that patients with severe factor XI deficiency have no excessive bleeding 
and on the contrary, patients with moderate, below the normal levels, factor activity 
suffer from extreme postoperative bleeding (Gomez et al, 2008). When there is a clear 
history of abnormal bleeding, FXI concentrate or fresh frozen plasma is the choice of 
treatment. In case of minor procedures and dental extractions tranexamic acid mouth-
wash alone may be adequate (Keeling et al, 2008). 
 
Factor VII deficiency is the most frequent among rare congenital bleeding disorders (1: 
500 000). Factor VII deficiency is the only congenital bleeding disorder characterized 
by isolated prolonged prothrombin time. Thus, its laboratory diagnosis is simple. Clini-
cal manifestations vary from severe life-threatening haemorrhages to miscellaneous 
minor bleeding (Lapecorella, Mariani 2008). Recombinant VIIa is the treatment of 
choice (Keeling et al, 2008). 
 
Factor V is the plasma cofactor for the prothrombinase complex. The activation of 
prothrombin to thrombin is regulated by this complex. The phenotype of patients with 
factor V deficiency seems to be less severe than the one of patients with haemophilia A 
or B. Thus, the risk of bleeding has limited correlation with levels of factor V (Huang, 
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Koerper, 2008). Treatment of bleeding episodes require fresh frozen plasma because no 
factor V-specific concentrate is available (Keeling et al, 2008). In cases of less severe 
mucosal bleeding, the use of antifibrinolytic agents alone may be sufficient (Huang, 
Koerper, 2008). 
 
Combined factor V and factor VIII deficiency is extremely rare (1: 1 000 000) and is 
associated with a mild to moderate bleeding tendency. Treatment requires a source of 
both factors V and VIII (Spreafico, Peyvandi, 2008). 
 
Factor XIII deficiency is a rare bleeding disorder with a high degree of heterogeneity in 
molecular basis. Thus it presents different clinical manifestations, severe bleeding, um-
bilical bleeding during the neonatal period, delayed soft tissue bruising, mucosal bleed-
ing and life-threatening intracranial haemorrhages. Poor wound healing and recurrent 
spontaneous abortions have been also associated with factor XIII deficiency (Hsieh, 
Nugent, 2008). The treatment of choice is factor XIII concentrate (Keeling et al, 2008).  
 
Fibrinogen deficiency can manifest as afibrinogemia and hypofibrinogemia (quantita-
tive defects) or dysfibrinogemia (qualitative defects). The most severe form is afibrino-
gemia with a prevalence of 1 in 1 000 000. The phenotype of the patient ranges from no 
clinical manifestations to extreme life-threatening bleeds (Acharya, Dimichele, 2008).  
Fibrinogen concentrate is the treatment of choice (Keeling et al, 2008). 
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1.4 Drugs that influence blood circulation 
  
In case of trauma, the mechanism of haemostasis and clotting formation is of crucial 
importance for the healing of the patient. The formation of an unwanted thrombus that 
will circulate as an embolous and jeopardise the function of many crucial organs, fol-
lows almost the same mechanism. Only in this case the stimulus is a malfunction of the 
blood circulation. An embolous can block the blood vessels and deprive the tissues of 
oxygen and nutrients leading to their failure and necrosis. Modern medicine provides a 
number of medicines that interfere with blood circulation and coagulation in order to 
prevent or deal with such a malfunction. However, such a therapy is inevitably accom-
panied by a high risk of unwanted bleeding after a surgery or trauma. 
 
Picture 3. Postoperative bleeding after extracting upper left molars in patient receiving 
anticoagulation therapy 
 
 
Picture 4. Extraoral aspect of the same patient 
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1.4.1 Parenteral anticoagulants  
 
The approved parenteral anticoagulants include indirect and direct. Indirect anticoagu-
lants exert their anticoagulant activity by activating antithrombin. These are unfraction-
ated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux and 
danaparoid. On the other hand, direct anticoagulants target thrombin. They include re-
combinant hirudins, bivalirudin and argatroban (Hirsh et al, 2008).   
Heparin is not absorbed through gastrointestinal mucosa. It must be given by continuous 
intravenous infusion (immediate onset of action) or subcutaneous injection (onset of 
action after 1-2 hours) (Majerus, Tollefsen, 2006, chap.54). 
One third of the administrated heparin binds to antithrombin and this fraction inacti-
vates a number of coagulation enzymes, including thrombin factor IIa and factors Xa, 
IXa, XIa and XIIa (shown with pink in Figure 3). Thrombin and factor Xa are most sen-
sitive to the effect of heparin/AT-III (Hirsh, Warketin et al, 2001). 
As heparin has rapid onset of action, especially when given intravenously, is used to 
initiate treatment of venous thrombosis and pulmonary embolism. It is also used to pre-
vent mural thrombosis after myocardial infarction and as treatment for patients with 
unstable angina and acute myocardial infarction (Hirsh et al, 2001). 
The biological limitations of heparin include heparin-induced thrombocytopenia and 
osteopenia. Osteopenia is caused because osteoclasts are activated by factors that os-
teoblasts release as heparin binds to them (Hirsh et al, 2001).  
Low molecular weight heparin has the advantage of a more predictable pharmacokinetic 
profile. This allows the use of weight adjusted subcutaneous administrations with no 
need for continuously laboratory monitoring. It doesn‟t cross the placenta and hasn‟t 
been related to foetal teratogenesis. In comparison to unfractionated heparin the inci-
dence of heparin-induced thrombocytopenia, as well as the possibility of bleeding or 
osteopenia, is lower (Majerus, Tollefsen, 2006, chap.54).  
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Table 3. Parenteral anticoagulants commercially available in Germany 
 
 
1.4.2 Oral anticoagulants 
 
 
The oral anticoagulants have been synthesized as derivatives of 4-hydroxycoumarin and 
of the related compound, indan-1,3-dione. Warfarin is widely used in United States of 
America while in Europe phenprocoumon is the drug of choice. They are antagonists of 
Vitamin K. Therapeutic doses aim at decreasing the total amount of each vitamin K-
dependent coagulation factor synthesized by the liver and diminishing their biological 
activity. The Vitamin K-dependent factors are II, VII, IX and X (shown in green colour 
in Figure 3). Some coagulation factors have a long half-life i.e. factor II has 50 hours 
half-life. This is why the full antithrombotic effect is achieved after several days. How-
ever, because of the more rapid reduction of factors with a short half-life, i.e. factor VII 
has 6 hours half-life, PT may be prolonged soon after administration (Majerus, Tollef-
 
active ingredient               brand name              manufacturer 
LMWH  
        Enoxaparin             Clexane                   Sanofi-Aventis 
        Reviparin                Clivarin                    Abbott 
        Dalteparin               Fragmin                   Pharmacia 
        Nadroparin              Fraxiparin                GlaxoSmithKline 
                                        Fraxodi                    GlaxoSmithKline 
        Tinzaparin               Innohep                    LEO 
        Certoparin               Mono-Embolex         Novartis 
Fondaparinux                 Arixtra                     GlaxoSmithKline 
Danaparoid                    Orgaran                    Essex Pharma 
Desirudin                        Revasc                    Canyon Pharma 
Bivalidurin                      Angiox                     The Medicines Company 
Argatroban                     Argatra                     Mitsubishi Ph. Dt. 
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sen, 2006, chap. 54). Related Vitamin K antagonists also impair the synthesis of antico-
agulant factors, protein C and S but this is outweighed by the effect of depressing the 
above mentioned coagulation factors (Zivellin et al, 1993).  
Oral anticoagulants are effective for primary and secondary prevention of venous 
thromboembolism or pulmonary embolism, for prevention of systemic embolism in 
patients with atrial fibrillation or prosthetic heart valves, for prevention of acute myo-
cardial infarction in patients with peripheral arterial disease and for prevention of 
stroke, recurrent infarction or death in patients who survived an acute myocardial in-
farction (Hirsh et al, 2003).  
The safety and effectiveness of anticoagulant therapy critically depends on maintaining 
the INR within the therapeutic range. Thus, once the INR becomes stable, regular moni-
toring is necessary every 4 weeks (Hirsch et al, 2003). 
It is of great importance that a list of substances can interact with oral anticoagulants 
increasing or decreasing their effect. More specifically, antiepileptic drugs, antifungal 
agents, hormones and hormones antagonists, retinoids and high intake of vitamin K can 
possibly decrease the anticoagulant effect. On the other hand, large amounts of alcohol 
especially when combined with a liver disease, aspirin and all non-steroidal anti-
inflammatory drugs, antibacterial agents, hormone antagonists, lipid lowering drugs, 
ulcer healing drugs and uricosuric agents can possibly increase the anticoagulant effect 
(Johnston, 1999, chap. 10). Apart from drugs and agents, a series of food and herbal 
supplements can also interact with oral anticoagulants. Fish oil, mango, grapefruit, avo-
cado, soy milk and many herbs are included in the list, each one with a different level of 
potentiation (Ansel et al, 2008).      
Contraindication for a therapy with oral anticoagulants are bleeding disorders such as 
thrombocytopenia, pregnancy, history of a recent surgery to the CNS or eye and any 
active bleeding site. Severe, uncontrolled hypertension, proliferative retinopathy, recur-
rent falls, poor compliance and alcoholism are also relative contraindications (Johnston, 
1999, chap. 10). 
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 Table 4. Oral anticoagulants commercially available in Germany 
 
 
 
 
Intrinsic pathway                                                    Extrinsic pathway 
 
XII                     XIIa 
 
                XI                    XIa 
 
                              IX                  IXa                 VIIa                  VII               
 
                                          X                 Xa                   X 
 
                        II (prothrombin)                             IIa ( thrombin) 
 
                                                         fibrinogen                                     fibrin 
 
 
Figure 3. Coagulation factors inactivated by heparin (shown in pink) and oral antico-
agulants (shown in green) 
 
active ingredient          brand name                    manufacturer 
Phenprocoumon      Falithrom                      Hexal  
                                   Marcumar                     MEDA Pharma 
                                   Marcuphen-CT             CT Arzneimittel 
                                   Phenpro AbZ                AbZ- Pharma 
                                   Phenprogamma            Wörwag  
                                   Phenpro-ratiopharm     Ratiopharm 
Warfarin-natrium      Coumadin                     Bristol Myers Squibb 
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1.4.3 Antiplatelet drugs 
 
Approximately 10
11
 platelets are produced every day, a level that can increase up to 10-
fold at times of increased need.  Platelets provide the initial haemostatic plug at sites of 
vascular injury. However, they can also participate in pathological thrombosis leading 
to stroke, myocardial infarction and peripheral vascular thrombosis (Majerus, Tollefsen, 
2006, chap.54). 
Antiplatelet drugs include aspirin, dipyridamole, thienopyridines (ticlodipine and clopi-
dogrel) and integrin aIIbß3 receptor antagonists (Patrono et al, 2008). 
 
1.4.3.1 Aspirin 
 
Cyclooxygenase enzyme (COX) is needed for prostaglandin and thromboxane synthe-
sis. Aspirin irreversibly inactivates the COX activity of prostaglandin H-synthase-1 and 
-2. Low-dose aspirin selectively inhibits COX-1, aiming at platelet inhibition, and high-
dose aspirin inhibits both COX-1 and COX-2, aiming also at inflammatory cells (Pa-
trono et al, 2008). 
The plasma concentration of aspirin reaches its peak 30 to 40 min after ingestion. Inhi-
bition of platelets is evident after 1 hour. The plasma concentration of aspirin has a half-
life of 15 to 20 min. However, as aspirin irreversibly inactivates COX-1, the platelet 
inhibitory effect lasts 8 to 10 days (platelets life span) (Patrono et al, 2008). 
Aspirin is used as treatment or prophylaxis in cases of stable or unstable angina, acute 
myocardial infarction or acute ischemic stroke, transient ischemic attack, severe carotid 
artery stenosis, men at high cardiovascular risk and polycythemia vera (Patrono et al, 
2008). 
When used for the platelet-inhibition effect, the most appropriate strategy is the lowest 
effective dose (50 to 100 mg/d for long term treatment) that maximizes its efficacy and 
minimizes its toxicity (Patrono et al, 2005).   
Aspirin can cause generalised bleeding abnormality when given to patients with under-
lying bleeding disorder or receiving an anticoagulant therapy. Aspirin can induce gas-
trointestinal toxicity, especially when gastric mucosal erosions related to use of non 
steroid anti-inflammatory drugs and Helicobacter pylori infection are underlying. Even 
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when administrated in low doses it can cause serious gastrointestinal bleeding and en-
teric-coated or buffered form offer no secure alternative.  Aspirin use can also result in 
major extracranial and intracranial haemorrhage, although the overall risk is difficult to 
assess (Patrono et al, 2008). 
 
1.4.3.2 Dipyridamole 
 
Dipyridamole is a vasodilator and has little or no benefit as antithrombotic drug (Maje-
rus, Tollefsen, 2006, chap.54). The fixed combination of modified-release dipyridamole 
and low-dose aspirin has been approved for stroke prevention. It is also used in combi-
nation with warfarin to provide primary prophylaxis to patients with a recent history of 
prosthetic heart valve surgery (Patrono et al, 2008). 
 
1.4.3.3.1 Ticlodipine  
 
Ticlodipine has been associated with hypercholesterolemia and neutropenia as well as 
with thrombocytopenia, aplastic anaemia and thrombotic thrombocytopenic purpura and 
therefore its therapeutic use is eliminated in patients with cerebral ischemia when aspi-
rin has failed, cannot be tolerated or is contraindicated (Patrono et al, 2008). 
 
1.4.3.3.2 Clopidogrel 
 
Clopidogrel is a prodrug, inactive in vitro and is metabolically transformed by the liver 
into a short-lived active platelet inhibitor (Patrono et al, 2008).   
The approved indications for Clopidogrel are to reduce the rate of stroke, myocardial 
infarction and death in patients with recent myocardial infarction or stroke, established 
peripheral arterial disease or acute coronary syndrome (Majerus, Tollefsen, 2006, chap. 
54). Simultaneous treatment with aspirin and Clopidogrel represents the standard care 
for patients with acute coronary syndrome and following coronary stenting. The combi-
nation of these two drugs is also used for the prevention of arterial thrombosis in many 
other vascular interventions (e.g. carotid or aortic stenting) (Darius, 2010). 
On repeated daily administration of low doses, the active metabolite of Clopidogrel has 
a pharmacodynamic pattern quite similar to that of aspirin in causing cumulative inhibi-
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tion of platelet function. Similar to aspirin, when Clopidogrel is administrated platelet 
function returns to normal 7 days after the last dose. Both the cumulative nature of the 
inhibitory effects and the slow rate of recovery of platelet function are consistent with 
acetylsalicylic acid and the active metabolite of Clopidogrel. Thus, they are causing a 
permanent defect in a platelet protein that cannot be repaired during the 24-hours doses 
interval and can only be replaced as a function turnover. This explains the effectiveness 
of the once-daily dose of both drugs (Patrono et al, 2008).  
 
1.4.3.4 Integrin inhibitors 
 
Platelet-integrin aIIbß3 is a dimeric glycoprotein receptor for fibrinogen and von Wille-
brand factor. By anchoring platelets to foreign surfaces and to each other, it enhances 
aggregation. Inhibition of this receptor blocks platelet aggregation. Three inhibitors of 
this receptor have been approved; abciximab, eptifibatide and tirofiban (Majerus, 
Tollefsen, 2006, chap.54).  
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active ingredient                         brand name         manufacturer 
Acetylsalicylic acid                Aspirin                Bayer Vital 
                                                 ASS                    Hexal, AbZ, ALIUD Pharma, CT-   
                                                                            Arzneimittel, ratiopharm, Wörwag, 
                                                                            Sandoz, STADApharm, TAD  
                                                Acesal                 Nycomed Deutschland 
                                                Godamed            Pfleger 
                                                HerzASS             Ratiopharm 
Dipyridamole (+ASS)            Aggrenox             Böhringer Ingelheim 
Ticlodipin                               Ticlodipin             ALIUD Pharma, CT Arzneimittel,  
                                                                            HEXAL, neuraxpharm, ratiopharm 
                                                                            Sandoz, STADApharm 
                                                Tiklyd                   Sanofi-Aventis 
Clopidogrel                            Clopidogrel          STADApharm, 1 A Pharma,, AbZ,  
                                                                            ALIUD Pharma, CT Arzneimittel, 
                                                                            Betapharm, HEXAL, ratiopharm, TAD 
                                                Clopidocor           Sandoz 
                                                Clopigamma        Wörwag 
                                                Iscover                 Bristol Myers Squibb 
                                                Plavix                   Sanofi-Aventis 
Abciximab                              ReoPro                 Lilly 
Eptifibatide                             Integrillin              GlaxoSmithKline 
Tirofiban                                 Aggrastat             Iroko/Chiesi 
 
Table 5. Antiplatelet drugs commercially available in Germany 
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1.5 Laboratory assessment of a possible bleeding patient 
 
The initial laboratory screening tests include complete blood count, prothrombin time, 
activated partial prothrombin time and thrombin time.  
Complete blood count reveals the platelet count. A platelet count less that 150 x 10
9
 /L 
suggests a thrombocytopenic disorder which must be further investigated. 
Prothrombin time (PT) evaluates the overall efficiency of the clotting factors of extrin-
sic and common pathway. An inherited or acquired deficiency of factors V, VII, X, 
prothrombin and fibrinogen can prolong PT, although the relationship is not linear. The 
development of an inhibitor against these factors or against a component of the PT reac-
tion can also prolong PT. The test measures the clotting time of plasma after adding 
tissue factor and calcium to hypocalcemic plasma. Normal rates are between 12 and 15 
seconds. However, every laboratory, depending on its methods and reagents, determines 
its own range of reference. The international normalised ratio (INR) is developed to 
reduce laboratory variability and to simplify monitoring of anticoagulation with war-
farin. It is calculated as a ratio of the patient‟s PT to the geometric mean of normal con-
trol subjects. 
Activated partial prothrombin time (aPTT) evaluates the overall efficiency of the clot-
ting factors of the intrinsic and common pathway.  Likewise, an inherited or acquired 
deficiency of factors V, VIII, IX, X, XI, XII, prothrombin, fibrinogen, kallikrein, high 
molecular weight kinogen, as long as the development of an inhibitor against these fac-
tors or against a component of the aPPT reaction can prolong aPPT.  The test measures 
the clotting time of plasma following the activation of contact factors without added 
tissue factor. Again in this case, the laboratory determines its own range.  
As discussed in chapter 1.1, the use of these screening tests to predict clinical bleeding 
is to be questioned. The commonly used clinical coagulation tests do not really reflect 
the complexity of haemostasis in vivo as the extrinsic and intrinsic pathways are actu-
ally interdependent in vivo. Any laboratory test result is not enough on its own and 
skilled interpretation and clinical correlation as well as comprehension of the coagula-
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tion mechanism are required in order to evaluate the true risk of bleeding (Romney, 
Glick 2009).  
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2 Aim of the study 
The aim of this study was to investigate the possible relation between postoperative 
bleeding and age, gender, medical history, medication, type of operation, place of op-
eration, preoperative, intraoperative and postoperative measures against bleeding after 
minor oral surgeries. This was accomplished by collecting data on all patients who were 
treated for postoperative bleeding in Oral and Maxillofacial Department of Regensburg 
Hospital from 2004 until 2009. 
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3 Materials and Methods 
 
3.1 Patients 
 
The patients selected for this study were obtained through IS-H med SAP program. This 
is a program module from GSD-Siemens used for healthcare facilities as a complete 
hospital information system. According to the DRG (Diagnosis-related group) classifi-
cation, patients classified under one of the following DRG codes were retrieved: T81.0 
(bleeding and haematoma as a complication of a surgery), 5-249.0 (other operations and 
measures in tooth region: arrest of bleeding), 5-279.0 (other operations and measures in 
oral and maxillofacial region: arrest of bleeding). The time period examined was from 
2004 until 2009. The total number of patients retrieved was 134. 
All patients classified as above, had undergone a minor surgical procedure in the oral 
region and then suffered from postoperative bleeding. In the majority of cases, the mi-
nor surgical procedure is a single or multiple tooth extraction at the upper or lower jaw. 
In few cases it can be root amputation, sinus lift augmentation, root scaling or prepros-
thetic operation. The operation was conducted either ambulant or inpatient in the Oral 
and Maxillofacial Surgery department of Regensburg University Hospital, or ambulant 
in a dental office in the region of Regensburg (alio loco). The patients who received 
ambulant treatment (either in our hospital or in a dental office) and suffered from post-
operative bleeding appeared in the emergency department of Regensburg hospital and 
were treated accordingly.  
 
Treatment of the patient with postoperative bleeding 
Once a patient presented himself in the emergency department of our hospital with 
postoperative bleeding, the first to be checked was the patient‟s history; special atten-
tion was given to the medication list. The history of the operation was also important. 
The patient was asked about the time and place of operation, the time after the operation 
until the bleeding occurred and measures taken until then. In cases of patients operated 
in our hospital, the above information was already known and documented. 
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In case of a light bleeding, the therapy of choice was the application of a haemostatic 
agent and sutures, if there were no sutures made. The haemostatic agents included hu-
man fibrinogen/human thrombin, collagen and oxidised regenerated cellulose. In case of 
bleeding that derived from bone, bone wax could also be used. The sutures used were 
normally absorbable because this allowed multiple, overlapping suturing. In case of 
arterial bleeding, an arrest of bleeding by using surgical diathermy was applied.  
In case that sutures were already done, the surgeon had to decide if over sutures were 
enough or if there was a need of a flap formation and approximation of wound edges in 
order to achieve a better haemostasis.  In case that a flap had been already made, there 
was the possibility of removing the sutures, inspecting the wound, adding additional 
haemostatic agents and re-approximating the wound edges (revision). 
If the bleeding could not be brought under control after taking local measures, an inpa-
tient treatment would follow. In this case, the patient was admitted for constant observa-
tion of the level of bleeding and monitoring of the blood values. As a measure against 
bleeding, patients under anticoagulation therapy often received substitution with low 
molecular weight heparin. 
Often the surgeon decided the manufacture and use of a splint. After taking an imprint 
of the teeth using alginate, a plaster was prepared and thereby a splint was produced. It 
aimed at pressing the extraction wound in order to stop the bleeding and protecting it 
from the mechanical load when eating. 
 
Measures taken preoperatively in patients operated in Oral and Maxillofacial Sur-
gery department of Regensburgs University hospital 
When the operation took place in the Oral and Maxillofacial Surgery department of Re-
gensburg hospital, many of the above measures were taken in advance in order to pre-
vent a possible bleeding. More specifically, for patients receiving anticoagulation ther-
apy or suffering from a bleeding disorder, special measures were taken before and after 
the surgery. Antiplatelet drugs, after contacting the internist of the patient and with his 
permission, were discontinued one week before the surgery. Oral anticoagulants, again 
after consulting the internist, were substituted by low molecular weight heparin subcu-
taneous injections or discontinued for one week before the surgery. Haemophilic and 
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von Willebrand patients received before and after the surgery, after consulting the hae-
matologist and according to factor screening, recombinant factor supplements or antifi-
brinolytic agents. 
As a standard measure for every patient with a higher risk of postoperative bleeding, a 
splint was prepared before the operation in the laboratory, as described above. More 
specifically, after taking an imprint of the teeth using alginate, the plaster was prepared 
and then the teeth that were about to be extracted were removed from the plaster, allow-
ing for the splint to be manufactured. 
A standardised measure when dealing with high risk patients was to keep them inpatient 
after the operation. This meant that patients stayed postoperatively under inpatient 
monitoring and could only be released when they were 24 hours free of bleeding.  The 
need of inpatient treatment depended on various parameters. Patients taking phenpro-
coumon or other anticoagulants, discontinued, substituted or current were treated inpa-
tient. Alike were treated patients with coagulation disorders and factor deficiencies.  
Patients with severe hepatopathy were treated inpatient, according to coagulation and 
blood values. When the patient was under therapy with salicylic acid that could be dis-
continued, in case of single tooth extractions and minor surgeries, an ambulant treat-
ment was possible. If there were more teeth to be extracted, or the discontinuing of sali-
cylic acid was not allowed, an inpatient treatment was necessary. In case of a double 
antiplatelet therapy an inpatient treatment was necessary. 
Patients receiving a splint after the operation were advised to wear it for four days con-
stantly. After four days the wound was inspected and if there was no bleeding, the splint 
could be removed and used only when eating to prevent wound injuries. The splint 
could be totally removed after the suture removal, if the wound healing was complete. 
Alike, patients that received a splint after the bleeding had to wear it constantly until the 
removal of the sutures. 
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Picture 5. A splint ready to be placed after tooth extractions in left mandible 
 
 
Picture 6. The splint in intraoral position  
 
A synopsis of the preoperative, intraoperative and measures taken after the bleeding is 
as followed:  
Preoperative measures  
1. Detailed medical history, medication list, personal or family history of bleeding 
2. Contact with internist if anticoagulation can be discontinued/substituted 
3. Imprint in order to manufacture a splint 
4. Arrangements for an inpatient operation when: 
     a. Coagulation disorders in medical history 
     b. Phenprocoumon to be discontinued/substituted/continued 
     c. Salicylic acid and other antiplatelets not allowed to be discontinued 
     d. Double antiplatelet therapy 
     e. Severe hepatopathy affecting blood values and clotting factors 
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Intraoperative measures 
1. Tooth extraction as atraumatic as possible  
2. Use of haemostatic agents (collagen tamponade, human fibrinogen/thrombin, oxi-
dised regenerated cellulose, tranexamic acid, bone wax) or diathermy 
3. Approximation of wound edges or multiple sutures  
4. Placement of the splint. If needed, underlaid with oxidised regenerated cellulose bap-
tised in tranexamic acid  
 
In case of bleeding, postoperative measures  
1. Local measures (haemostatic agents, over sutures) 
         a. Discharge if bleeding is minimal and stops,  
2. Approximation of wound edges, splint manufacture and inpatient admittance            
3.  Substitution of phenprocoumon with low molecular weight heparin injections if 
taken currently  
4.  Administration of antifibrinolytic agents or factor supplements according to medical    
history  
5. Constant monitoring of blood values; transfusion if necessary 
 
 
Picture 7. Post-extraction alveolus after removal of tooth 43 in patient receiving anti-
coagulation therapy 
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Picture 8. Post-extraction alveolus of picture 7 filled with collagen sponge 
 
 
Picture 9. Approximation of wound edges after multiple extractions in maxilla 
 
An analysis of the data reveals differences between the procedure that was followed 
when operating a patient in alio loco and in the Oral and Maxillofacial Surgery Depart-
ment of Regensburg University hospital. Important parameters are the discontinuation 
of antiplatelet therapy and the discontinuation or substitution with low molecular weight 
heparin of anticoagulation therapy. The use of haemostyptic measures (splint, haemo-
styptic agents) is extremely limited in the dental offices. Moreover, in dental offices, 
concerning the wound care after the operation, simple sutures are used in few cases 
while the approximation of the wound edges and a primary healing comes almost never 
in question.   
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3.2 Statistical methods 
 
 
The statistical analysis was carried out using the programme Medas (Grund EDV-
Systeme, Margetshöchheim, Germany) and the significance tests were conducted using 
U-test by Mann and Whitney, chi-square test, chi-square test by Fisher and Yates, 
Kruska- Wallis one-way analysis of variance and exact chi-quadrat test by Mehta and 
Patel.  
More specifically: 
In order to describe the relationship between two classified variables, the chi-square test 
of maximum likelihood was generally calculated. When the expected values were low, 
the exact chi-square test by Fisher and Yates was computed in 4 field tables and in lar-
ger tables the exact chi-square test by Mehta and Patel.  
The U-test by Mann and Whitney was used to compare measured values between two 
groups when a Gaussian distribution of measured values could not be attained. For a 
limited number of patients, under 20, the exact U-test was used. 
The Kruskal-Wallis one-way analysis of variance replaced the U-test when three or 
more groups were compared. 
In order to compare the test results quantitatively, p-values were calculated.  A p value 
below 0.05 was considered significant and the result was interpreted as significant. The 
p-values were indicated with star-symbols: 
p <0.05 with *, p <0.01 with ** and p <0.001 ***. 
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4 Results 
4.1 Demographic data 
 
The 134 patients of this survey were 16 to 90 years old, with a mean age of 59.9 ± 17.1 
years.  The median was 65 years with a 68%-CI from 40.3 to 75 years. 71 patients 
(53%) were male and 63 patients (47%) were female (Figure 4). 
0%
2%
4%
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18%
20%
<19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 >90
male
female
Figure 4. Age and gender. The columns represent the percentage of patients according 
to age group and gender (n=134) 
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4.2 Medical history 
 
The vast majority of the patients suffered from hypertension and heart diseases. 14 pa-
tients (10,3%) suffered from coagulation disorders (including 4 haemophilic patients) 
while 8 patients (5,9%) suffered from liver failure. 10 patients (7,4%) had in their medi-
cal history a stent operation, 5 patients (3,7%) a bypass operation, 17 patients (12,6%) a 
stroke, 10 patients (7,4%) a myocardial infarction, 9 patients (6,7%) a heart pacemaker, 
11 patients (8,2%) a thrombosis and 2 patients (1,5%) a lung infarction (Table 6). 
 
Disease n % 95%-CI 
Hypertension 41 30.5970% 23.0889% 39.2375%  
Coronary heart disease 30 22.3881% 15.8339% 30.5609%  
Heart failure 7 5.2239% 2.1258% 10.8664%  
Heart rhythm disorder 26 19.4030% 13.2834% 27.3209%  
Cardiac pacemaker 9 6.7164% 3.1169% 12.7337%  
Heart valve disease 9 6.7164% 3.1169% 12.7337%  
Myocardial infarction 10 7.4627% 3.6365% 13.6484%  
Stent  10 7.4627% 3.6365% 13.6484%  
Bypass 5 3.7313% 1.2225% 8.9339%  
Stroke 17 12.6866% 7.7786% 19.8078%  
Thrombosis 11 8.2090% 4.1692% 14.5527%  
Lung infarction 2 1.4925% 0.1813% 5.2875%  
Peripheral Arterial Disease 5 3.7313% 1.2225% 8.9339%  
Coagulation disorders 10 7.4627% 3.6365% 13.6484%  
Haemophilia 4 2.9851% 0.8192% 7.9344%  
Diabetes mellitus 13 9.7015% 5.2674% 16.3338%  
Nephropathy 8 5.9701% 2.6124% 11.8069%  
Hepatopathy 8 5.9701% 2.6124% 11.8069%  
Table 6. Diseases in medical history, number and percentage of the 134 patients. CI = 
Confidence Interval 
 
4.2.1 Demography and medical history 
 
The mean age of the patients that suffered from hypertension was 67 years, from coro-
nary heart disease 68 years, from heart failure 71 years, from heart rhythm disorder 69 
years, from thrombosis 69 years and with a heart pacemaker 71 years. The patients suf-
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fering from haemophilia had a mean age of 22 years and from hepatopathy 46 years. All 
results were statistically significant (Table 7). 
 
 
   Age [Years]   
Disease  n MW ST  p 
Hypertension yes 41 66.610 10.908  0.014* 
 no 93 57.011 18.571   
Coronary heart disease yes 30 67.767 8.573  0.018* 
 no 104 57.692 18.332   
Heart failure yes 7 71.429 10.533  0.040* 
 no 127 59.315 17.245   
Heart rhythm disorder yes 26 69.577 8.448  0.0012** 
 no 108 57.630 17.913   
Heart pacemaker yes 9 71.000 6.062  0.029* 
 no 125 59.152 17.422   
Thrombosis yes 11 69.182 14.176  0.038* 
 no 123 59.122 17.197   
Haemophilia yes 4 22.000 8.165  0.00015*** 
 no 130 61.115 15.988   
Diabetes Mellitus yes 13 70.538 10.852  0.0092** 
 no 121 58.810 17.340   
Nephropathy yes 8 71.750 6.409  0.028* 
 no 126 59.198 17.352   
Hepatopathy yes 8 46.500 8.767  0.0025** 
 no 126 60.802 17.213   
Table 7.  Age and diseases in medical history. MW = Mean, ST = Standard Deviation, 
 p according to U-Test by Mann and Whitney 
 
 
The male patients presented more often a coronary heart disease, a history of myocar-
dial infarction or have had a Stent operation. These results were statistically significant 
(Table 8). 
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   Gender   
   male  female   
Disease  n % n %  p 
Coronary heart disease yes 21 29.58% 9 14.29%  0.032 * 
 no 50 70.42% 54 85.71%   
Myocardial infarction yes 9 12.68% 1 1.59%  0.019*fy 
 no 62 87.32% 62 98.41%   
Stent  yes 9 12.68% 1 1.59%  0.019*fy 
 no 62 87.32% 62 98.41%   
Table 8. Gender and diseases in medical history. Number and percentage of the pa-
tients. The percentages refer to the columns, i.e. to gender. p according to Chi-Square-
Test or (fy) to exact Chi-Quadrat-Test by Fisher and Yates 
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4.3 Anticoagulation/antiplatelet therapy 
 
40 patients (30%) were under no anticoagulation therapy. 15 patients (11%) were taking 
phenprocoumon, 23 patients (17%) acetylsalicylic acid, 5 patients (4%) Clopidogrel and 
one patient was under continuous heparin infusion therapy. 32 patients (24%) were un-
der low molecular weight heparin (LMWH) therapy. 27 patients (20%) had phenpro-
coumon with LMWH substituted, 19 patients (14%) had discontinued phenprocoumon 
therapy and 6 patients (4%) had discontinued therapy with acetylsalicylic acid (Table 9, 
Figure 5). 
 
Medication  Number % 
Phenprocoumon no 73 54.48 % 
 discontinued 46 34.33 % 
 yes 15 11.19 % 
Aspirin no 105 78.36 % 
 discontinued 6 4.48 % 
 yes 23 17.16 % 
Clopidogrel no 125 93.28 % 
 discontinued 4 2.99 % 
 yes 5 3.73 % 
LMWH no 102 76.12 % 
 yes 32 23.88 % 
Heparin no 133 99.25 % 
 yes 1 0.75 % 
Table 9. Anticoagulation/antiplatelet therapy, in case of  phenprocoumon discontinued 
includes also substituted. Number and percentage of patients.  n = 134. LMWH= Low 
Molecular Weight Heparin 
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Figure 5. Anticoagulation therapy discontinued, substituted or current taken at the day 
of operation. The columns represent the number of patients (n=134). LMWH=Low Mo-
lecular Weight Heparin  
 
 
4.3.1 Demography and medication 
 
The mean age, statistical significant, of the patients receiving phenprocoumon is 68,2 
years old and of the ones receiving acetylsalicylic acid 67,7 years. The mean age of pa-
tients under low molecular weight heparin therapy is 66,9 years (Table 10). 
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   Age   
Medication   n MW ST   
Phenprocoumon yes 15 68.267 8.137   
 stopped/substituted 46 66.544 9.697  0.00085*** 
 no 73 54.082 19.861   
Aspirin yes 23 67.783 14.722   
 stopped/substituted 6 60.500 7.714  0.031* 
 no 105 58.200 17.626   
LMWH no 102 57.745 18.413  0.016*U 
 yes 32 66.969 9.499   
Table 10. Age and anticoagulants/antiplatelets. LMWH=Low Molecular Weight Hepa-
rin, MW = Mean, ST = Standard Deviation, p according to Kruska-Wallis analysis of 
variance or (U) to U-Test by Mann and Whitney 
 
Among the 7 medication groups presented in table 10 there were no differences con-
cerning the gender (p = 0.44 in exact Chi-Quadrat-Test by Mehta and Patel). The pa-
tients receiving anticoagulants or antiplatelets -discontinued/substituted or not- had a 
mean age of 66.8 ± 10.7 years. The patients with no such a medication, however, were 
only 44.4 ± 19.3 years old (p < 0.000005*** in U-Test by Mann und Whitney). 
 
4.3.2 Medical history and medication 
 
 
92,68% of the patients suffering from hypertension were under anticoagulation or anti-
platelet therapy. Under anticoagulation or antiplatelet therapy were also 90% of the pa-
tients suffering from coronary heart disease, 96,15% of the patients with heart rhythm 
disorder, 100% of the patients after a myocardial infarction, 94,12% of the patients after 
a stroke, 100% of the patients with thrombosis and 12,5% of the patients with hepatopa-
thy. No patient suffering from haemophilia received anticoagulation therapy. All the 
above mentioned  results were statistically significant (Table 11).  
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Anticoagulation/antiplatelet 
 therapy 
  
   yes  no   
Disease  n % n %  p 
Hypertension yes 38 92.68% 3 7.32%  0.000034*** 
 no 55 59.78% 37 40.22%   
Coronary heart disease yes 27 90.00% 3 10.00%  0.0033** 
 no 66 64.08% 37 35.92%   
Heart failure yes 7 100.00% 0 0.00%  0.10fy 
 no 86 68.25% 40 31.75%   
Heart rhythm disorder yes 25 96.15% 1 3.85%  0.00020***fy 
 no 68 63.55% 39 36.45%   
Heart pacemaker yes 9 100.00% 0 0.00%  0.057fy 
 no 84 67.74% 40 32.26%   
Heart valve failure yes 7 77.78% 2 22.22%  0.72fy 
 no 86 69.35% 38 30.65%   
Myocardial infarction yes 10 100.00% 0 0.00%  0.032*fy 
 no 83 67.48% 40 32.52%   
Stent yes 9 90.00% 1 10.00%  0.28fy 
 no 84 68.29% 39 31.71%   
Bypass yes 5 100.00% 0 0.00%  0.32fy 
 no 88 68.75% 40 31.25%   
Stroke yes 16 94.12% 1 5.88%  0.0085** 
 no 77 66.38% 39 33.62%   
Thrombosis yes 11 100.00% 0 0.00%  0.034*fy 
 no 82 67.21% 40 32.79%   
Lung infarction yes 1 100.00% 0 0.00%  1.0fy 
 no 92 69.70% 40 30.30%   
Periph. arterial disease yes 5 100.00% 0 0.00%  0.32fy 
 no 88 68.75% 40 31.25%   
Coagulation disorder yes 3 30.00% 7 70.00%  0.0082**fy 
 no 90 73.17% 33 26.83%   
Haemophilia yes 0 0.00% 4 100.00%  0.0073**fy 
 no 93 72.09% 36 27.91%   
Diabetes mellitus yes 12 92.31% 1 7.69%  0.11fy 
 no 81 67.50% 39 32.50%   
Nephropathy yes 6 75.00% 2 25.00%  1.0fy 
 no 87 69.60% 38 30.40%   
Hepatopathy yes 1 12.50% 7 87.50%  0.00092***fy 
 no 92 73.60% 33 26.40%   
Table 11. Diseases in medical history and anticoagulation/antiplatelet therapy. Num-
ber and percentage of the patients. The percentages refer to the rows, i.e. to the dis-
eases. p according to Chi-Quadrat-Test or (fy) to exact Chi-Quadrat-Test by Fisher 
and Yates 
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4.4 Primary operation 
 
42 % of the patients were operated in Regensburg hospital and 58% in alio loco; docu-
mentation about one patient is missing (Figure 6). 
 
 
42%
58%
Regensburg hospital
alio loco
 
Figure 6. Place of operation. Percentages of patients according to place of operation 
(n=134) 
 
 
88,81% of the patients bled after a simple tooth extraction, 2,99% after a surgical ex-
traction, 2,99% after an apicectomy, 2,24% after an augmentation of the sinus, 2,24% 
after a root scaling and 0,75% underwent no operation and bled spontaneously (Figure 
7). 
3% 3% 2%
2%
1%
89%
Tooth extraction
Surgical extraction
Apicectomy
Augmentation
Root scaling
none
 
Figure 7. Type of operation. Percentages of the patients according to type of operation 
(n=134) 
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74,44% of the patients underwent an operation in maxilla and 37,59% in mandible. 10% 
of the patients were operated in anterior maxilla, 58,18% in posterior maxilla and one 
patient both in posterior and anterior maxilla. 2,52% of the patients were operated in 
anterior mandible and 27,73% in posterior mandible. No one was operated in both re-
gions of the mandible. More specifically in maxilla, 8,96 % of the patients were oper-
ated in lateral incisor region, 5,97% in canines, 14,92% in pre-molars, 49,35% in molars 
and 20,9% in wisdom teeth region. In mandible, no patients were operated in incisors 
and canine region, 16,66% were operated in pre-molars, 43,34% in molars and 40% in 
wisdom teeth region (Table 12). 
 
  
   Maxilla  Mandible 
  Number % Number % 
Operation yes 99 74.44 50 37.59 
 no 34 25.56 83 62.41 
 unknown 1 –  1 – 
Localization no 34 30.91 83 69.75 
 anterior 11 10.00 3 2.52 
 posterior 64 58.18 33 27.73 
 both 1 0.91 0 0.00 
 unknown 24 – 15 – 
Tooth 1 0  0  
 2 6 8.96 0  
 3 4 5.97 0  
 4 9 13.43 1 3.33 
 5 1 1.49 4 13.33 
 6 20 29.85 5 16.67 
 7 13 19.40 8 26.67 
 8 14 20.90 12 40.00 
 unknown 67 – 104 – 
Table 12. Localization of the primary operation according to mandible or maxillary 
localization. Number and percentage of the 134 patients 
 
 
83 patients (62%) were operated only in maxilla, 34 patients (25%) only in mandible 
while 16 patients (12%) in both. In one patient localization was not documented. 
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4.4.1 Demography and Operation 
 
The patients operated in maxilla were significantly older, with a mean age of 62.3 ± 
20.6 years, in comparison to patients operated in mandible which had a mean age of 
53.1 ± 20.6 years (p = 0.034* in U-Test by Mann and Whitney). 
3 patients operated in anterior mandible had a mean age of 73.7 ± 8.5 years, 33 patients 
operated in posterior mandible had a mean age of 51.2 ± 20.6 years while 83 patients 
that were not operated in mandible had a mean age of 62.6 ± 15.2 years ( p = 0.0088 in 
Kruskal-Wallis analysis of variance). 
The lower wisdom teeth were extracted in 12 patients which were significantly younger, 
with a mean age of 33.5 ± 17.9 years. 
There were also differences in age concerning the type of operation. 4 patients that un-
derwent a surgical extraction had a mean age of 24.8 ± 16.4 years. Between the other 5 
groups, there were no statistical significant differences, with a mean age of 61.0 ± 16.3 
years (p = 0.75 in Kruskal-Wallis analysis of variance). 
 
4.4.2 Medication and type of operation 
 
77,55% of the patients operated in maxilla were under anticoagulation therapy while 
only 58% of the patients operated in mandible were under the same therapy. 59,21% of 
patients operated in maxilla were under therapy with phenprocoumon –discontinued, 
substituted or not- and 40,78% under therapy with aspirin or Clopidogrel. All results are 
statistically significant (Table 13). 
  43 
  Maxilla   
  yes  no   
 n % n %  p 
Anticogulation/antiplatelet   yes 76 77.55% 16 47.06%  0.0012 ** 
therapy no 22 22.45% 18 52.94%   
phenprocoumon 11 14.47% 3 18.75%   
Aspirin/Clopidogrel 25 32.89% 0 0.00%   
phenprocoumon substituted 20 26.32% 7 43.75%  0.018 * 
phenprocoumon stopped 14 18.42% 5 31.25%   
Asp./Clopid. substituted/stopped 6 7.89% 1 6.25%   
  Mandible   
  yes  no   
 n % n %  p 
Anticoagulation/antiplatelet  yes 29 58.00% 63 76.83%  0.023 * 
therapy no 21 42.00% 19 23.17%   
Table 13. Anticoagulation/antiplatelet therapy and localization of the operation. Num-
ber and percentages of patients, percentages refer to the columns, i.e. to the localiza-
tion. n = 133 patients 
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4.5 Primary wound care measures 
 
In 87,31% of patients (117) were wound care measures taken. Among them, 3 (3%) 
were ambulant operated and 114 (97%) inpatient (p = 0.028* in exact Chi-Quadrat-Test 
by Mehta and Patel). 
Among the 117 patients who received wound care measures, 14,17% received a splint. 
In 56,71% of the patients sutures were made, in 30,59% of the cases a flap was used in 
order to approximate the wound edges, 2,23% of the patients received collagen, in 
1,49% of the patients desmopressin was administrated and in 0,7% of the cases tranex-
amic acid was used. 25,3% of the patients stayed inpatient after the operation (Table 
14). 
Wound care measures n % 95%-CI 
Measures after operation 117 87.3134% 80.1922% 92.2214%  
Splint 19 14.1791% 8.9682% 21.5092%  
Suture 76 56.7164% 47.8851% 65.1570%  
Approximation of wound 
edges-Flap 
41 30.5970% 23.0889% 39.2375%  
Collagen  3 2.2388% 0.4641% 6.4033%  
Desmopressin  2 1.4925% 0.1813% 5.2875%  
Tranexamic acid  1 0.7463% 0.0189% 4.0877%  
Inpatient stay 34 25.3731% 18.4345% 33.7526%  
Table 14. Wound care after operation. Number and percentage of n=134 patients. CI = 
Confidence Interval 
 
 
 
4.5.1 Demography and wound care measures 
 
The two patients that received desmopressin as part of the therapy against bleeding were 
significant younger than the rest of the patients, 27.0  ± 9.9 years old, in comparison to 
the rest of the patients who received no desmopressin, 60.4 ± 16.8 years (p = 0.023* in 
U-Test by Mann and Whitney). 
The patients that were inpatient operated had a mean age of 66.5 ± 8.5 years, not sig-
nificant older than the ones treated outpatient which were 57.7 ± 18.7 years old (p = 
0.055 in U-Test by Mann and Whitney). 
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4.5.2 Anticoagulation therapy and wound care measures 
 
Wound care measures were taken in 66,67% of the patients under current phenprocou-
mon therapy. In 95,65% of the patients who had phenprocoumon therapy substituted, 
there were also wound care measures taken. These results are statistically significant. 
39,13% of the patients taking aspirin were operated inpatient while 50% of the patients 
who had aspirin discontinued, were also inpatient operated. However, these results are 
not statistically significant. In 40% of the patients who received therapy with Clopido-
grel, an approximation of the wound edges was used while the same measure was taken 
in all patients who had Clopidogrel discontinued. These results are statistically signifi-
cant (Table 15). 
 
 
 
      n % n % n %  p 
   Phenprocoumon   
   no  stopped  yes   
Wound care measures yes 63 86.30% 44 95.65% 10 66.67%  0.018 *   
 no 10 13.70% 2 4.35% 5 33.33%   
Splint yes 7 9.59% 11 23.91% 1 6.67%  0.070     
 no 66 90.41% 35 76.09% 14 93.33%   
   Aspirin   
   no  stopped  yes   
Inpatient stay yes 22 20.95% 3 50.00% 9 39.13%  0.087     
 no 83 79.05% 3 50.00% 14 60.87%   
   Clopidogrel   
   no  stopped  yes   
Flap yes 35 28.00% 4 100.00% 2 40.00%  0.0065 ** 
 no 90 72.00% 0 0.00% 3 60.00%   
Inpatient stay yes 29 23.20% 3 75.00% 2 40.00%  0.076     
 no 96 76.80% 1 25.00% 3 60.00%   
Table 15. Anticoagulation/antiplatelet therapy and wound care measures. Number and 
percentage of the patients, percentage refers to the columns, i.e. to the medication. p 
according to Chi-Quadrat-Test. n = 134 patients           
 
 
73,33 % of patients who received phenprocoumon were operated ambulant, in Regens-
burg hospital or in alio loco, while 26,27% were operated inpatient. 59,26 % of patients 
who had phenprocoumon substituted were operated ambulant and 40,74% inpatient. 
73,68% of patients who had phenprocoumon discontinued were operated ambulant and 
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26,32% inpatient. 64 % of the patients under Aspirin or Clopidogrel therapy were oper-
ated ambulant and 36% inpatient. 57,14% of patients who had aspirin or Clopidogrel 
discontinued were operated ambulant and 42,86% inpatient. The results are statistically 
significant (Table 16). 
 
   Operation   
   inpatient  ambulant   
  n % n %  p 
Group Phenprocoumon 4 26.67% 11 73.33%   
 Aspirin/Clopidogrel 9 36.00% 16 64.00%   
 
Phenprocoumon 
substituted 
11 40.74% 16 59.26%   
 Phenprocoumon stopped 5 26.32% 14 73.68%  0.0043** 
 Aspirin/Clopid. stopped 3 42.86% 4 57.14%   
 no anticoagulation therapy 2 5.00% 38 95.00%   
Table 16. Inpatient or ambulant operation and anticoagulation/antiplatelet therapy. 
Number and percentage of the patients, percentage refers to the rows, i.e. to the medi-
cation. p according  to exact Chi-Quadrat-Test by Mehta and Patel. n = 134 patients                
 
4.5.3 Operation and wound care measures 
 
100% of the patients operated in Regensburg hospital received wound care measures 
after the operation in comparison to 79,22% of the patients treated in alio loco. In 
71,43% of the patients operated in Regensburg hospital a flap was used and simple 
sutures were made only in 28,57% of the patients. In alio loco, 77,92% of the patients 
received simple sutures and only 1,30% a flap. In 28,57% of the patients operated in 
Regensburg hospital and in 3,90% of the patients operated in alio loco a splint was used. 
All above results are statistically significant. Although not statistically significant, 
collagen tamponade, desmopressin and tranexamic acid were not at all used when the 
operation took place in alio loco. 60,71% of the patients operated in Regensburg 
hospital received an inpatient treatment after the operation. All patients operated in alio 
loco were ambulant patients. (Table 17, Figure 8).  
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   Place of operation   
   
Regensburg 
hospital 
 alio loco   
  n % n %  p 
Wound care measures yes 56 100.00% 61 79.22%  0.000013*** 
 no 0 0.00% 16 20.78%   
Suture yes 16 28.57% 60 77.92%  <0.00000005*** 
 no 40 71.43% 17 22.08%   
Flap yes 40 71.43% 1 1.30%  <0.00000005*** 
 no 16 28.57% 76 98.70%   
Splint yes 16 28.57% 3 3.90%  0.000044*** 
 no 40 71.43% 74 96.10%   
Collagen tamponade yes 3 5.36% 0 0.00%  0.072fy 
 no 53 94.64% 77 100.00%   
Desmopressin yes 2 3.57% 0 0.00%  0.18fy 
 no 54 96.43% 77 100.00%   
Tranexamic acid yes 1 1.79% 0 0.00%  0.42fy 
 no 55 98.21% 77 100.00%   
inpatient stay yes 34 60.71% 0 0.00%  <0.00000005*** 
 no 22 39.29% 77 100.00%   
Table 17. Place of operation and type of wound care measures taken. Number and per-
centage of patients, the percentage refers to the rows, i.e. the measures taken. p accord-
ing to exact Chi-Quadrat-Test by Mehta and Patel. n = 134 patients    
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Figure 8. Type of wound care measures taken in Regensburg hospital and in alio loco. 
The columns represent the percentage of patients (n=134). 
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44,54% of tooth extractions took place in Regensburg hospital and 55,46% in alio loco. 
75% of surgical extractions took place in Regensburg hospital and 25% in alio loco, 
while all apicectomies, sinus augmentations and root scaling took place in alio loco. The 
results are statistically significant. 
Wound care measures were taken in 89,92% of tooth extractions, 100% of surgical ex-
tractions, 100% of apicectomies and 100% of  sinus augmentations. No wound care 
measures were taken in 10,08% of the tooth extractions and in 100% of root scaling 
(Table 18). 
 
Type of operation n % n %  p 
      Place of operation   
  
Regensburg 
hospital 
 alio loco   
Tooth extraction 53 44.54% 66 55.46%   
Surgical extraction 3 75.00% 1 25.00%   
Apicectomy 0 0.00% 4 100.00%  0.047*mp 
Augmentation 0 0.00% 3 100.00%   
Root scaling 0 0.00% 3 100.00%   
      Wound care measures   
  yes  no   
Tooth extraction 107 89.92% 12 10.08%   
Surgical extraction 4 100.00% 0 0.00%   
Apicectomy 4 100.00% 0 0.00%   
Augmentation 2 100.00% 0 0.00%  0.0011**mp 
Root scaling 0 0.00% 3 100.00%   
keine 0 0.00% 1 100.00%   
Table 18. Type of operation and place of operation, wound care measures. Number and 
percentage of patients, percentage refers to the rows, i.e. type of operation. p according 
to exact Chi-Quadrat-Test by Mehta and Patel. n = 134 patients.                
 
 
In Regensburg hospital 47/56 Patienten (84%) were in maxilla operated while alio loco 
only 52/77 (68%, p = 0.029* in Chi-Quadrat-Test). In maxilla, a flap was made in 35/99 
patients (35%) otherwise in mandible only in 6/34 patients (18%, p = 0.045* in Chi-
Quadrat-Test). 
Patients operated in maxilla were treated more often inpatient (31/99 = 31%), in com-
parison to patients operated only in mandible (3/34 = 9%, p = 0.0051** in Chi-Quadrat-
Test).   
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A splint was used only in 4 patients operated in maxilla (4/46 = 8%), while in mandible 
a splint was used in 15 patients (15/83 18%, p = 0.095 in Chi-Quadrat-Test).  
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4.6 Therapy against bleeding 
 
In 26,87% of the patients simple sutures were made in order to deal with the postopera-
tive bleeding. Over sutures were used in 45,52% of the patients. A flap was made in 
11,94% of the cases, while in 5,22% of the patients the flap was once again approxi-
mated and sutured. 29,85% of the patients received a splint after they bled while in 3 
cases the splint which was already placed, was fixated. In 25,37% of the patients oxi-
dised regenerated cellulose was used, in 4,48% collagen, in 2,24% bone wax, in 1,49% 
human fibrinogen/thrombin, in 22,39% tranexamic acid and in 7,46% diathermy was 
used. 4,48% of the patients required a transfusion, in 2,98% was phytomenadione ad-
ministrated, one patient was given FIII/VWF complex and in 2,24% of the patients 
phenprocoumon had to be substituted with low molecular weight heparin (Table 19). 
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Therapy against bleeding  Number % 
Suture yes 36 26.87 % 
 new suture  2 1.49 % 
 no 96 71.64 % 
Over sutures yes 61 45.52 % 
 no 73 54.48 % 
Flap yes 16 11.94 % 
 once again approximated 7 5.22 % 
 no 111 82.84 % 
Splint yes 40 29.85 % 
 fixation 3 2.24 % 
 no 91 67.91 % 
Oxid. regen. cellulose yes 34 25.37 % 
 no 100 74.63 % 
Collagen yes 6 4.48 % 
 no 128 95.52 % 
Bone wax yes 3 2.24 % 
 no 131 97.76 % 
Revision yes 9 6.72 % 
 no 125 93.28 % 
Transfusion yes 6 4.48 % 
 no 128 95.52 % 
Diathermy yes 10 7.46 % 
 no 124 92.54 % 
Tranexamic acid yes 30 22.39 % 
 no 104 77.61 % 
Human fibrinogen/thrombin yes 2 1.49 % 
 no 132 98.51 % 
Phytomenadione yes 4 2.98 % 
 no 130 97.02 % 
FVIII/VWF complex yes 1 0.75 % 
 no 133 99.25 % 
Phenprocoumon substitution yes 3 2.24 % 
 no 130 97.76% 
Table 19. Measures against bleeding. Number and percentage of n = 134 patients 
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4.6.1 Demography and therapy against bleeding 
 
The mean age of patients receiving a splint was 65 years; the patients requiring a trans-
fusion had an average age of 72 years. All results statistically significant (Table 20). 
 
   Age   
Therapy against  
bleeding 
 n MW ST  p 
Splint yes 43 65.116 14.026  0.032* 
 no 91 57.505 17.999   
Transfusion yes 6 72.333 5.391  0.036* 
 no 128 59.367 17.298   
Table 20. Age and measures against bleeding. MW = Mean, ST = Standard Deviation, 
p according to U-Test by Mann and Whitney. Splint yes includes also fixation of a splint 
already in use. 
 
 
4.6.2 Medical history and therapy against bleeding 
 
 
30% of the patients that suffered from bleeding disorders needed a transfusion. This 
result is statistically significant (Table 21).  
 
   Bleeding disorders   
   yes  no   
   n % n %  p 
Transfusion  yes 3 30.00% 3 2.42%  0.0054**fy 
 no 7 70.00% 121 97.58%   
Table 21. Bleeding disorders and therapy against bleeding. Number and percentage of 
the patients, percentage refers to the column, i.e. to disease. p according to exact Chi-
Quadrat-Test by Fisher and Yates 
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4.6.3 Anticoagulation therapy and therapy against bleeding 
 
As part of the measures against bleeding, transfusion was needed in 21,05% of the pa-
tients who had phenprocoumon discontinued and in 5% of the patients who received no 
anticoagulation therapy (Table 22). 
 
   Transfusion    
   yes  no   
 Medikations-Cluster n % n %  p 
1 Phenprocoumon 0 0.00% 15 100.00%   
2 Aspirin/Clopidogrel 0 0.00% 25 100.00%   
3 Phenprocoumon substituted 0 0.00% 27 100.00%   
4 Phenprocoumon stopped 4 21.05% 15 78.95%  0.048*mp 
5 Aspirin/Clopid. stopped 0 0.00% 7 100.00%   
6 no medication 2 5.00% 38 95.00%   
7 Heparin 0 0.00% 1 100.00%   
Table 22. Medication-clusters and transfusion to deal against the bleeding. Number and 
percentage of the patients, percentage refers to the rows, i.e. to clusters. p according to  
exact Chi-Quadrat-Test by Mehta and Patel 
 
 
4.6.4 Primary wound care measures and therapy against bleeding 
 
When primary wound care measures were taken, there was a need of approximation of 
the wound edges after the bleeding in only 6,84% of the patients and 52,14% of the pa-
tients required only over sutures. On the contrary, when there were no wound care 
measures taken, 47,06% of the patients needed after the bleeding approximation of 
wound edges ( p=0.0000026*** according to Chi-Quadrat-Test, p= 0.00017*** accord-
ing to exact Chi-Quadrat-Test by Mehta and Patel). 
 
When a splint was already placed as part of the wound care measures, in 15,79% of the 
patients it had to be fixated. When there was no splint initially used, in 34,78% of the 
patients there was one after the bleeding produced and placed (Table 23). 
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   primary use of splint   
   yes  no   
Therapy  
against 
bleeding 
 n % n %  p 
Splint  yes 0 0.00% 40 34.78%   
 fixation 3 15.79% 0 0.00%  0.000014***mp 
 no 16 84.21% 75 65.22%   
Table 23. Primary use of splint and therapy against bleeding. Number and percentage of 
the patients, percentage refers to the columns, i.e. to primary measures taken. p accord-
ing to exact Chi-Quadrat-Test by Mehta and Patel 
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4.7 Time and duration of bleeding 
 
After the bleeding, 91,79% of the patients (123) were treated inpatient. 90 out of the 
123 patients were admitted after the bleeding occurred while the rest 33 were already 
inpatient. 4,48% of the patients (6) were treated only ambulant. 3,73% of the patients 
(5) were already inpatient in another clinic for other medical reasons (Figure 
9).
4%
96%
ambulant
inpatient
Figure 9. Percentage of patients treated ambulant or inpatient after the bleeding 
(n=134). 
 
The time of appearance of the bleeding varied between 1 and 28 days, on average 2.88 ± 
4.22 days (median one day with 68%-CI from 1 until 5 days). 5% of the patients bled 
after the 10
th
 postoperative day (Figure 10). More specifically, 3 patients bled on the 
12
th
 postoperative day, one on the 13
th
, one on the 20
th
, one on the 24
th
 and one patient 
bled on the 28
th
 postoperative day (Figure 10). 
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 Figure 10. Postoperative day when bleeding occurred. The columns represent number 
of patients (n=134).  
 
The duration of the inpatient stay varied between 1 and 24 days. Ambulant treatment is 
considered of 0 days duration (Figure 11). 
On average the inpatient treatment lasted 5.37 ± 5.38 days (median 3 days with 68%-CI 
from 2 until 9.7 days).  
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Figure 11. Duration of inpatient treatment after bleeding in days. 0 days stands for am-
bulant treatment of the bleeding. The columns represent the number of patients (n=129, 
excluding the ones inpatient in another department). 
 
 
The later the bleeding occurred, the longer lasted the inpatient treatment of the patient.  
(tau = 0.29, p < 0.000005*** according to Kendall rank correlation).  
In case of bleeding at the first or second day, 15/95 (16%) of the patients required an 
inpatient treatment for 7 or more days. If the bleeding occurred after the third day, then 
12/30 (40%) of the patients had to stay more than 6 days inpatient. (p = 0.0073** in 
Chi-Quadrat-Test). 
 
4.7.1 Demography and time until bleeding 
 
The older the patient, the more lasted his inpatient treatment (tau = 0.15, p = 0.014*) 
while the time period between the operation and the time of bleeding shows no correla-
tion with age (tau = 0.09, p = 0.12, both according to Kendall rank correlation). 
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The duration of the inpatient treatment as well as the time of bleeding shows no correla-
tion with gender. 
 
4.7.2 Medical history and time until bleeding 
 
Patients with a coagulation disorder bled, on average, the fifth postoperative day, pa-
tients with haemophilia on the eleventh postoperative day while patients with liver dis-
ease on the sixth postoperative day. All results are statistically significant (Table 24). 
 
   n MW ST  p(U) 
Disease   Day of bleeding   
Coagulation disorders yes 10 5.500 4.301  0.00055*** 
 no 120 2.667 4.159   
Haemophilia yes 4 11.250 11.673  0.012* 
 no 126 2.619 3.580   
Hepatopathy yes 8 6.250 4.496  0.0018** 
 no 122 2.664 4.127   
Table 24. Time in days until bleeding. MW = Mean, ST = Standard deviation, p accord-
ing to U-Test by Mann and Whitney 
 
 
4.7.3 Anticoagulation therapy and duration of inpatient stay 
 
 
30 patients receiving LMWH  stayed inpatient after the postoperative bleeding signifi-
cant more days (7.2 ± 5.7) than patients receiving no LMWH or other anticoagulants 
(4.8 ± 5.2) (p = 0.0045** in U-Test by Mann and Whitney). 
 Patients under phenprocoumon therapy had to stay for an inpatient treatment, on aver-
age, 4,46 ± 3,46  days, while patients who had phenprocoumon discontinued or substi-
tuted required an inpatient treatment of 7,95 ± 6,29 days. These results are statistically 
significant. Patients under therapy with aspirin had to stay inpatient 3,09 ± 2,09 days 
and patients who had aspirin discontinued stayed 3 ± 2,19 days. These results are 
scarcely not significant. 
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More specifically, statistically significant results are as followed: Patients under Aspirin 
or Clopidogrel therapy stayed inpatient 3,08 ± 2,02 days, patients who had phenpro-
coumon substituted 7,08 ± 5,1 days, patients who had phenprocoumon discontinued 
9,10 ± 7,52 days, patients who had aspirin or Clopidogrel discontinued or substituted 
5,57 ± 7,72 days, patients receiving no medication 4,17 ± 4,87 days and one patient un-
der heparin therapy had to stay inpatient 3 days (Table 25). 
 
 Duration of inpatient stay [d]   
Medication  n MW ST  p 
Phenprocoumon yes 15 4.46667 3.46135   
 discontinued/substituted 44 7.95455 6.29490  
0.00005 
*** 
 no 70 3.94286 4.48471   
Aspirin yes 21 3.09524 2.09535   
 discontinued 6 3.00000 2.19089  0.052 
 no 102 5.98039 5.81562   
Group Phenprocoumon 15 4.46667 3.46135   
 Aspirin/Clopidogrel 23 3.08696 2.02064   
 Phenprocoumon substituted 25 7.08000 5.16333   
 Phenprocoumon discontin. 19 9.10526 7.52695  0.0011 ** 
 Aspirin/Clopid. discontin. 7 5.57143 7.72134   
 no medication 39 4.17949 4.87135   
 Heparin 1 3.00000 -   
Table 25. Duration of inpatient stay after bleeding under anticoagulation therapy. MW 
= Mean, ST = Standard Deviation, p according to Kruskal-Wallis analysis of variance 
 
 
 
4.7.4 Operation and duration of inpatient stay, time until bleeding 
 
Inpatient stay after the bleeding of 54 patients, operated in Regensburg hospital, lasted 
7.0 ± 6.5 days, while patients initially operated in alio loco, had to stay only 4.3 ± 4.2 
days (p = 0.0049** in  U-Test by Mann and Whitney). 
 
When the operation took place in Regensburg hospital, the bleeding occurred after 3,51 
± 4,71 days. When the patient was operated in alio loco, the bleeding occurred after 
2,43 ± 3,80 days. The bleeding in cases of tooth extraction occurred 3,07 ± 4,40 days 
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after the operation, while in all other cases the bleeding occurred the next day (1,15 ± 
0,37). These results, however, are not statistically significant (Table 26). 
 
  postoperative bleeding [d]   
primary operation  n MW ST  p(U) 
Place   Regensburg hospital 54 3.519 4.713  0.061 
 alio loco 76 2.434 3.803   
Type Tooth extraction 117 3.077 4.408  0.066 
 other 13 1.154 0.376   
Type Tooth extraction 117 3.077 4.408   
 Surgical extraction 4 1.000 0.000   
 Apicectomy 4 1.000 0.000  0.22 kw 
 Augmentation 2 1.000 0.000   
 root scaling 3 1.667 0.577   
Table 26. Time until bleeding in days according place and type of operation. MW = 
Mean, ST = Standard Deviation, p according to U-Test by Mann and Whitney or (kw) 
according to Kruskal-Wallis analysis of variance 
 
 
 
4.7.5 Wound care measures and duration of inpatient stay, time until bleeding 
 
When there were sutures made after the operation, the bleeding occurred after 2,71 ± 
4,45 days (statistically significant), while when approximation of the wound edges was 
performed, the bleeding occurred after 3,4 ± 4,43 days (statistically not significant) (Ta-
ble 27). 
 
Wound care measures  n MW ST  p(U) 
   Day of bleeding   
Suture yes 74 2.716 4.458  0.046* 
 no 56 3.107 3.916    
Flap yes 40 3.400 4.431  0.069 
 no 90 2.656 4.130   
Table 27. Wound care measures and time until bleeding. MW = Mean, ST = Standard 
deviation, p according to U-Test by Mann and Whitney 
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4.7.6 Therapy against bleeding and duration of inpatient stay 
 
When there was a flap made, in order to deal with the bleeding, the inpatient stay lasted 
3,66 ± 3,22 days, in comparison to 5,42 ± 5,6 days when there was no flap made. All 
above results are statistically significant (Table 28). 
 
   n MW ST  p 
   
Duration of inpatient 
stay [d] 
  
Flap yes 15 3.66667 3.22195   
  once again 7 8.14286 4.81070  0.040 *kw 
 no 107 5.42991 5.60174   
Table 28. Therapy against bleeding and duration of inpatient stay. MW = Mean, ST = 
Standard deviation, p according to Kruskal and Wallis analysis of variance 
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4.8 Changes over the years 
 
In the year 2004, 9 patients (6,72%) were treated, in 2005 20 patients (14,93%), in 2006 
21 patients (15,67%), in 2007 33 patients (24,63%), in 2008 27 patients (20,15%) and in 
2009 24 patients (17,91%) (Figure 12). 
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Figure 12. Percentage of patients with postoperative bleeding according to year of op-
eration (n=134). 
 
4.8.1 Demography and year of operation 
 
Among the years, no change was noticed in age or gender . 
 
4.8.2 Anticoagulation therapy and year of operation 
 
Among the years, there was no change noticed in the number of patients receiving anti-
coagulants. 
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4.8.3 Type of operation and year of operation 
 
Among the years, there was no change noticed in the number of patients who were op-
erated in Regensburg hospital and in alio loco. There was also no change noticed in the 
number of operations in upper and lower jaw. 
 
4.8.4 Wound care measures and year of operation 
 
In the last years, wound care measures are less taken. Sutures were made mostly earlier; 
the approximation of wound edges is more common in the last years. Inpatient opera-
tion is more common in the last years. A splint has been already in use since 2004. The 
results are statistically significant (Figure 13). 
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Wound care measures and year of operation 
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Figure 13. Wound care measures according to year of operation. Each area of the cir-
cle represents the number of patients. ■ =  Wound care measures, ■ = Sutures,                   
■ = Approximation of wound edges-Flap, ■ = Splint, ■ = inpatient operation,  □ =no. 
 
 
 
4.8.5 Therapy against bleeding and year of operation 
 
In order to deal with the postoperative bleeding, over sutures were mostly used earlier 
and have been lately replaced by approximation of wound edges. Revision is also most 
common in the last years while haemostatic agents are more popular in the last years. 
Human fibrinogen was not used until 2009. All results are statistically significant (Fig-
ure 14). 
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Therapy against bleeding and year of operation 
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Figure 14. Therapy against bleeding according to year of operation. Each area of the 
circle represents the number of patients. ■ = Suture, ■ = New sutures (revision),              
■ =  Over sutures, ■ = Flap, ■ = Flap revision, ■ = Splint, ■ = Splint fixated,                 
■ = Oxidized cellulose, ■ =Inpatient admittance,  ■ = already inpatient,                          
□ =  no.  
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4.8.6 Time until bleeding, duration of inpatient stay and year of operation 
 
The duration of the inpatient stay because of the postoperative bleeding decreased over 
the years (tau = -0.20, p = 0.00062***) while the time after the operation until bleeding 
remained unchanged (tau = -0.04, p = 0.50, both according to Kendall Rank correla-
tion). 
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5 Discussion 
After noticing an increase in the number of patients coming to our clinic with a postop-
erative bleeding after minor oral surgery, we decided to study a possible relation be-
tween postoperative bleeding and age, gender, medical history, medication, type of op-
eration, place of operation, preoperative, intraoperative and postoperative measures. 
 
5.1 Demographic data and medical history  
 
In our study, 68% of the patients were between 40,3 and 75 years old. The above results 
were expected because at this age group patients suffer from disorders that require anti-
coagulation therapy. According to the statistical fact sheet of American Heart Associa-
tion, 71,3 % of general male population and 75,1% of general female population aged 
from 60 until 79 years present cardiovascular diseases. For ages between 40 and 59 
years old the percentage is 39,1% for males and 39,5% for females. The percentages 
climb to 83% and 92% for males and females, respectively, in the age of 80+, while at 
the age of 20 until 39 years old, cardiovascular disorders are present only in 14,8% of 
male and 9,4% of female population (American Heart Association, 2007). In our study 
group, less than 2% of the patients are between 16 and 39 years old. A small number of 
patients in that age takes anticoagulation therapy.  
In general population of white people aged 20 years and older, 8,5% have coronary 
heart disease (American Heart association, 2011). In our study group the percentage of 
patients with coronary heart disease ranges between 15,83% und 30,56. Haemophilia in 
general population is present in 0,0053- 0,020% (Venkateswaran L, 1998). The high 
percentage of patients suffering from haemophilia in our results is expected because 
these patients are more likely to present postoperative bleeding than the general popula-
tion. 
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5.2 Anticoagulation therapy 
 
Among the patients who presented postoperative bleeding, 34,33% were patients under 
phenprocoumon therapy which was discontinued or substituted on the day of the opera-
tion. This fact raises the question whether the substitution or discontinuation of phen-
procoumon therapy is necessary or effective before minor surgery in oral and maxillofa-
cial area. Of course, we did not have information concerning the nutrition or alternative 
drugs used by the patients that could effect the normalization of haemostasis and the 
INR values of the patients on the day of surgery. In the study of Schulman et al, al-
though warfarin had been discontinued five days before the operation, 7% of the pa-
tients did not normalize their prothrombin at the desired levels for surgery (Schulman et 
al, 2008). 
Indeed, several publications strongly disagree with discontinuing anticoagulation ther-
apy before dental procedures. Devani et al suggest that there is no justification in dis-
continuing warfarin before dental procedures, provided that INR is between 2.0 and 4.0 
and local haemostatic measures are used (Devani et al, 1998). Wahl considers a myth 
that patients receiving anticoagulation therapy experience more postoperative bleeding 
complications than patients with normal coagulation when undergoing a dental proce-
dure. He concludes that when anticoagulation therapy is interrupted, serious embolic 
complications, including death, are three times more likely to occur. He also points out 
that consulting the patients‟ physician is not the answer to the problem as many physi-
cians do not understand dental procedures and “simply following a physician‟s order is 
unlikely to be an effective legal defence if the dentist is charged with failure to exercise 
reasonable professional judgement” (Wahl, 2000). Jeske and Suchko conclude that the 
literature does not support routine discontinuation of anticoagulation therapy in patients 
undergoing dental procedures and suggest effective haemostatic measures and high 
level of awareness intra and postoperatively (Jeske, Suchko, 2003).  
Van Diermen et al, after assessing different guidelines on the management of patients 
using antithrombotic drugs in dental surgery according to Appraisal of Guidelines for 
Research and Evaluation (AGREE), strongly recommend the guidelines of Perry et al, 
as well as those of Aframian et al with certain alterations (van Diermen et al, 2009). 
Perry et al suggest that in the majority of patients undergoing dental extraction, oral 
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anticoagulation should not be discontinued (Perry et al, 2007). Aframian et al suggest 
that only when INR exceeds 3,5 and invasive or complicated procedures are planned, 
discontinuing warfarin should be discussed with the physician. Moreover, low-dose 
(until 100 mg) aspirin therapy should not be interrupted for outpatient dental procedures 
(Aframian et al, 2007).  
 
5.3 Primary operation 
 
The vast majority of the patients suffered from postoperative bleeding after having a 
tooth extracted. It comes as a surprise that only 2,99% of the operations was a surgical 
extraction. Taking into consideration that a surgical extraction means cutting gingival 
tissue and bone, one could have expected more patients suffering from bleeding after a 
surgical extraction. Indeed, blood flow in alveolar mucosa is significantly higher than in 
free gingiva (Kerdvongbundit et al, 2002). The only possible explanation is that after 
cutting tissue the surgeon has to make sutures providing subsequently a more effective 
haemostasis than that after removing a tooth where the alveolus is left open. We also 
have to take into account the possibility that the surgeons who confronted with the 
bleeding in Regensburg hospital inaccurately documented surgical extractions as simple 
extractions. 
Surprisingly, almost 75% of the postoperative bleedings came from maxilla and mostly 
from its posterior region. Posterior mandible, anterior maxilla and anterior mandible 
follow in this order.  
A comparison of maxillary and mandibular mineral densities has proven that the mean 
bone mineral density of the mandible was twice that of the anterior maxilla and both 
were significantly greater that the bone mineral density of the posterior maxilla (Devlin 
et al, 1998). However, there was no correlation found between mineralization density 
and cortical proportion of vascular space (Kingsmill et al, 2007). 
The majority of the patients receiving anticoagulation therapy suffer from cardiological 
disease. Evidence for a link between periodontal disease and several systemic diseases, 
mostly cardiological, is growing rapidly (Williams et al, 2008). The most probable teeth 
to be extracted because of the periodontal disease are the teeth of maxilla and mainly 
the molars (Chambrone et al, 2010, Hirschfeld, Wasserman, 1978, McFall 1982). So a 
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possible explanation for the high prevalence of bleeding in upper molars is the high 
prevalence of upper molars being extracted.  
Patients that bled after a wisdom tooth extraction were significantly younger. This result 
comes as no surprise taking into consideration that wisdom teeth are more often ex-
tracted in young people. 
The number of patients operated in all dental offices of Regensburg region is much 
greater than the ones operated in Regensburg Oral and Maxillofacial Surgery Depart-
ment. Subsequently, one could expect that the great majority of the patients suffering 
from a postoperative bleeding would have been operated in alio loco. However, 42% of 
the patients who presented postoperative bleeding were operated in Regensburg hospital 
and bled despite all the wound care measures. Of course, Oral and Maxillofacial Sur-
gery Department of Regensburg hospital treats mostly patients at high risk for bleeding 
and therefore, the prevalence of bleeding is greater. 
One patient who was under anticoagulation therapy bled spontaneously without any 
history of trauma. Anticoagulation therapy can consist of „double-edged sword‟ be-
tween thrombosis prevention and bleeding (May et al, 2008). Periodontitis is a chronic 
inflammation characterized by lymphocytic (T and B cell) and monocytic infiltrate, 
connective tissue destruction, and bone resorption while clinically it is characterised by 
gum bleeding (Moutsopoulos, Madianos, 2006). Patients under anticoagulation are 
prone to spontaneous bleeding and concerning oral and maxillofacial area this can occur 
in the presence of periodontitis. Moreover, awareness is necessary after root scaling in 
patients under anticoagulation therapy.  
 
5.4 Primary wound care measures 
 
All patients operated in Regensburg hospital received precaution wound care measures. 
It is important to note that when no wound care measures were taken, the patients were 
always operated in alio loco. This means that in many cases, patients receiving antico-
agulation therapy or having bleeding disorders were operated ambulant in dental offices 
and the dentists did not take any haemostatic measures. What is of great importance is 
whether the dentists had been aware of the patients‟ medical history and chose not to 
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take any measures or if they failed taking an accurate medical history. In almost 80% of 
the cases operated by dentists in alio loco, the wound care measure taken was a simple 
suture and in only 1,30% of the cases was an approximation of the wound edges the 
choice of wound treatment. On the other hand, 71% of the patients operated in Regens-
burg hospital received an approximation of the wound edges. A more limited familiari-
zation of the general dentists with surgical techniques is to be expected and therefore, a 
simple suture is often their treatment of choice. The question that rises is the need of 
acquaintance of the dentists with surgical skills as part of their basic education or at 
least more extended referral to hospitals or oral surgeons. The use of a splint postopera-
tively is more common in Regensburg hospital. Only 3,90% of the patients operated in 
alio loco received a splint from their dentist after the surgery. Although not statistically 
significant it has to be pointed out that collagen tamponade was never used by a dentist 
as a precursory measure. In case of operation in Regensburg hospital it was used in 
2,23% of the cases. Again, there is a need of familiarization of the general dentist with 
the haemostatic agents available. 
Aframian et al suggest the use of fibrin glue, gelatine sponges, oxidised cellulose or 
tranexamic mouthwash after dental procedures in patients receiving anticoagulants 
(Aframian et al, 2007). 
Surprisingly, almost 74% of the patients receiving phenprocoumon on the day of the 
operation were operated ambulant. Once again, it is unclear whether this was due to lack 
of information with regard to the patients‟ medication or, instead, whether the dentist 
was aware of their history and decided to operate them without inpatient treatment. 
However, one can conclude that in cases of minimal surgeries, i.e. one tooth extraction, 
there is always the possibility of an ambulant operation with a known risk of postopera-
tive bleeding. In all cases, the patient should be informed of the possible bleeding risk 
and a high level of awareness in case of a bleeding is necessary.  Indeed, Perry et al 
suggest the referral of patients receiving anticoagulants to a hospital-based oral and 
maxillofacial surgeon, when INR is unstable and patients suffer simultaneously from 
liver or renal disease, thrombocytopenia or are under antiplatelet therapy (Perry et al, 
2007).  
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5.5 Therapy against bleeding 
 
Therapy against bleeding includes suturing or approximation of wound edges in almost 
all cases. However, when a flap was made, the bleeding stopped earlier and patients 
were earlier discharged in comparison to patients who received only sutures after the 
bleeding. 
The surgeons in Regensburg hospital seem to be familiar with haemostatic agents and 
the use of a splint. Despite all local measures, three patient receiving  phenprocoumon 
continued to bleed during their inpatient treatment and therefore phenprocoumon ther-
apy was substituted. 
A complete schema in order to confront bleeding involves inpatient treatment with con-
stant monitoring. An inpatient treatment assures constant control of the amount of 
bleeding, of the blood values and immediate intervention if necessary. A soft food diet 
which will protect the wound from mechanical trauma is also guaranteed.  
A blood transfusion was necessary in 5% of the patients. More specifically, erythrocyte 
concentrates were transfused in six patients in order to prevent or correct the symptoms 
and signs of a lack of oxygen in tissues. Among the six patients, two were under discon-
tinued phenprocoumon therapy, one suffered from leukaemia, one suffered from throm-
bocytopenia and two patients suffered from anaemia and received phenprocoumon 
which was at that time discontinued. Surprisingly, it was these patients who had discon-
tinued phenprocoumon before the surgery who needed postoperatively transfusion.  
 In 2,24% of the cases, the splint, which was already in use, had to be fixated. Often, 
especially in case of edentulous jaws, the splint needs to be fixated with a screw in order 
to be stable and effective.  
One can observe that when there where wound care measures taken after the extraction, 
postoperatively over sutures were enough to stop the bleeding. When there were no 
wound care measures taken, the approximation of wound edges is the therapy of choice 
for stopping the bleeding. 
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5.6 Time and duration of bleeding 
 
Only 4,48% of the patients who presented postoperative bleeding were allowed to return 
home after treatment. Excluding the patients who were already inpatient as part of the 
precaution measures, 73,17% (90/123) of the patients who presented with a bleeding at 
the emergency room were treated inpatient. This implies a severe degree of bleeding. 
One should, however, take into consideration that all patients were not treated by the 
same surgeon and inevitably, the admittance criteria were subjective.  
The vast majority of the patients, 86 patients, bled on the first postoperative day while 
116 patients bled until the fifth day. One can assess the results assuming that the pa-
tients came immediately after the bleeding occurred and had not wasted a day or more 
waiting for the bleeding to stop automatically or trying to find a way to reach the hospi-
tal.  
When the bleeding occurred after the 10
th
 postoperative day, and assuming that there 
was no wound trauma during chewing, the existence of a disorder in the healing process 
would be most probable which, in combination with the underlying disease or medica-
tion intake, led to the bleeding. Patients with a coagulation disorder, haemophilia or 
liver disease bled much later than the ones taking anticoagulation therapy while patients 
with haemophilia bled later than all patients. Subsequently, especially for patients with 
coagulation disorders, one should be highly aware of bleeding several days after the 
operation. On the day that the sutures are removed and later on, there is a high possibil-
ity of postoperative bleeding. Patients should be advised to protect the wound, espe-
cially when chewing, for several days after the suture removal. Furthermore, the use of 
resorbable sutures in order to avoid the minimal trauma of suture removal is suggested. 
The duration of the inpatient stay depended on medical history. All patients with coro-
nary heart diseases had to be treated inpatient.  
An average of 68% of the patients had to stay from 2 until 9,7 days inpatient after the 
bleeding occurred. Surprisingly, in some cases the duration of the inpatient treatment 
lasted for more than 20 days. However, we have to notice that Figure 5 also includes 
patients who were admitted before the bleeding occurred. For this group of patients the 
duration of the inpatient stay begins on the operation day which is not always the day of 
bleeding.  
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The older the patient, the longer is his inpatient treatment. Presumably, this has to do 
with the condition of his general health and the severity of the underlying diseases.  
What can be of great importance is that patients taking phenprocoumon, had to stay 
inpatient significantly less than patients who had phenprocoumon discontinued or with 
low molecular weight heparin substituted. Although scarcely statistically significant, 
patients taking aspirin and patients who had discontinued their aspirin therapy before 
the operation, had to stay inpatient the same amount of days. This questions the efficacy 
and need of substituting or discontinuing anticoagulation/antiplatelet therapy before oral 
surgeries.  
Although the results are not statistically significant, it could be of importance that the 
bleeding after a tooth extraction occurred on average on the second day after the opera-
tion, whereas in the cases of sinus augmentation, apicectomy, root scaling or surgical 
extraction the bleeding is to be expected on the first postoperative day. 
 
5.7 Changes over the years 
 
An increase in the number of patients treated with postoperative bleeding is noticed 
after the year 2007. It is impossible to know if this is due to the increase of the number 
of teeth being extracted. Possibly, as years go by, patients suffering from heart diseases 
are increasing in number and hypertension is becoming „a rising tide‟ (Fields et al, 
2004). As a result, the number of patients in anticoagulation/antiplatelet therapy is also 
increasing and the risk of postoperative bleeding after tooth extraction in the general 
population is greater. However, no change was noticed over the years in the number of 
patients receiving anticoagulants. As there was no change noticed in the number of pa-
tients operated in Regensburg hospital and patients operated in other dental clinics, a 
possible explanation would be that in the last years, dentists having to deal with a post-
operative bleeding tend to send the patients to hospital, instead of confronting with the 
bleeding themselves.  
Concerning the wound care measures taken after the operation, lately there is an in-
crease in the number of patients in which no suture or other method of haemostasis was 
used. Taking into consideration that there was no change noticed in the number of pa-
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tients operated in Regensburg hospital and patients operated in other dental clinics, one 
can assume that dentists have taken earlier more often wound care measures after the 
operation than they did in the last years. And when measures were taken, assuming 
mostly in patients operated in Regensburg hospital, then, in the last years, simple su-
tures are being replaced by approximation of wound edges. The use of tranexamic acid 
is more common in the last years; the inpatient admittance of high risk patients after the 
operation is also more common in the last years.  
Over the years, the duration of the inpatient treatment after the bleeding has decreased. 
A possible explanation would be that lately the means to confront bleeding are more 
effective. Human fibrinogen was used for the first time in 2009 and approximation of 
the wound edges has been established in the last years. Tranexamic acid has been more 
often in use after 2007. It seems that haemostatic agents have been established in the 
daily surgical routine over the past years when confronting with postoperative bleeding. 
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6 Summary and conclusion  
The aim of this study was to investigate the possible relation between postoperative 
bleeding and age, gender, medical history, medication, type of operation, place of op-
eration, preoperative, intraoperative and postoperative measures against bleeding after 
minor oral surgeries. This was accomplished by collecting data on all patients who were 
treated for postoperative bleeding in Oral and Maxillofacial Department of Regensburg 
Hospital from 2004 until 2009. In the majority of cases, the minor surgical procedure 
was single or multiple tooth extraction at the upper or lower jaw (88,81%) and in few 
cases it was root amputation (2,99%), sinus lift augmentation (2,24%), root scaling 
(2,24%) or spontaneously (0,75%). The operation was conducted in Oral and Maxillo-
facial department of Regensburg hospital or in alio loco. A number of patients suffered 
from coagulation or liver disorders (16,2%) and the majority was under anticoagula-
tion/antiplatelet therapy (70%). Wound care measures, such as the approximation of 
wound edges (11,94%) and the use of haemostatic agents (53,73%) or a splint (29,85%), 
were used in many patients. Many patients were operated inpatient (24,62%) while oth-
ers were admitted inpatient after the bleeding (67,16%). 
The patients selected as material for this study, 134 in total, were obtained through IS-H 
med SAP program (GSD-Siemens). The patients classified under one of the following 
DRG codes (Diagnosis-related group classification) were retrieved: T81.0 (bleeding and 
haematoma as a complication of a surgery), 5-249.0 (other operations and measures in 
tooth region: arrest of bleeding), 5-279.0 (other operations and measures in oral and 
maxillofacial region: arrest of bleeding).  
The statistical analysis was carried out with the programme Medas (Grund EDV-
Systeme, Margetshöchheim, Germany) and the significance tests were made using U-
Test by Mann and Whitney, Chi-Square Test, Chi-Square Test by Fisher and Yates, 
Kruska- Wallis analysis of variance and exact Chi-Quadrat Test by Mehta and Patel. 
The results were significant at p<0,05. 
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 Patients with heart or arterial diseases are more likely to present postoperative 
bleeding because of the anticoagulation therapy they are receiving. Dentists 
should take accurate medical history placing emphasis on medication list. 
 When deciding to discontinue anticoagulation, one should take seriously into 
consideration the possible embolic complications. The final decision should be 
taken in correspondence with the physician. The physician must be adequately 
informed about the nature of the operation. However, the dentist is also obliged 
to “exercise reasonable professional judgement” (Wahl, 2000). 
 We suggest no discontinuation of aspirin before single extractions and in case of 
multiple extractions or more invasive procedures, additional inpatient surveil-
lance. In case of phenprocoumon, we suggest no discontinuation, and substitu-
tion only in case of more invasive procedures. In all cases of phenprocoumon 
therapy we consider an inpatient treatment necessary. 
 Haemophilia patients should always be treated in hospital environment and a 
haematologist should always be consulted in case of a need to administrate re-
placement factors. 
 In patients with liver disease, the severity of hepatopathy will determine the pre-
cautious measures and the need of ambulant or inpatient treatment. 
 The most expected site to bleed is posterior maxilla. High awareness is needed 
especially when extracting upper molars. 
 The bleeding is more likely to occur on the first or second postoperative day. 
However, the risk of bleeding remains for several days after the operation and 
potentially  after the suture removal as well. 
 There is a need for dentists to be familiar with the haemostatic agents available 
which together with several tight sutures can provide, in many cases, adequate 
haemostasis.  
 The use of splint is highly recommended especially after ambulant surgeries. 
 Patients receiving anticoagulants and suffering from periodontitis can potentially 
bleed after root scaling or spontaneously. 
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 Lege artis treatment of postoperative bleeding includes often inpatient treatment 
where blood values are constantly monitored and transfusion of erythrocyte con-
centrate is anytime possible. 
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7 Zusammenfassung und Schlussfolgerung 
 
Das Ziel dieser Studie war, mögliche Korrelationen zwischen einer postoperativen 
Nachblutung in der Mundhöhle und Parametern wie Alter, Geschlecht, Vorerkrankung, 
Medikation, Art der Operation, Ort der Operation, prä-, intra- und postoperative blutstil-
lende Maßnahmen darzustellen.  
Dazu wurden die Daten von insgesamt 134 Patienten, die mit einer postoperativen 
Nachblutung im Bereich der Mundhöhle in der Klinik und Poliklinik der Mund- Kiefer- 
und Gesichtschirurgie in den Jahren 2004 bis 2009 vorstellig wurden, gesammelt und 
analysiert. Generiert wurden die Patienten anhand der DRG Kodierung des SAP-
Betriebssystems (GSD-Siemens). Folgenden Kodierung wurden untersucht: T81.0 (Blu-
tung und Hämatom als Komplikation einer Operation), 5-249.0 (andere Operationen 
und Maßnahmen im Zahnbereich: Blutstillung, 5-279.0 (andere Operationen und Maß-
nahmen im Mund-Kiefer-Bereich: Blutstillung). 
Die statistische Auswertung erfolgte mit dem Programm Medas (Grund EDV-System, 
Margetshöchheim, Deutschland). Zur Auswertung der Ergebnisse dieser Studie wurden 
folgende Tests herangezogen: U-Test nach Mann und Whitney, Chi-Quadrat-Test, Chi-
Quadrat-Test nach Fisher und Yates, Kruska - Wallis Varianzanalyse und exakter Chi-
Quadrat-Test nach Mehta und Patel. Als Signifikanzniveau der Testergebnisse wurde 
ein p-Wert kleiner als 0,05 festgesetzt. 
Die chirurgischen Eingriffe wurden in der eigenen Klinik und Poliklinik für Mund-, 
Kiefer- und Gesichtschirurgie sowie durch niedergelassene Zahnärzte, Oral- oder MKG-
Chirurgen durchgeführt. In den meisten Fällen (88,81%) traten die Nachblutungen nach 
Extraktion einzelner oder mehrerer Zähne des Ober- und Unterkiefers auf. Seltener 
führten Wurzelspitzeresektion (2,99%), sinus lift augmentationen (2,24%), parodontale 
Kürettagen (2,24%) oder spontan (0,75%) zu einer verstärkten postoperativen Blutung.  
Als kausale Ursache der Nachblutung lag bei den meisten Patienten (16,2%) eine Stö-
rung der Blutgerinnung vor. Hierbei handelte es sich um Patienten mit eingeschränkter 
Leberfunktion (5,97%) oder mit einer hereditären Gerinnungsstörung wie einem Von-
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Willebrand-Jürgens-Syndrom (7,46%)  oder einer Hämophilie A (2,98%). Den größten 
Teil (70%) stellten jedoch Patienten mit einer antikoagulatorischen Therapie dar.  
Als therapeutische Maßnahme wurde zumeist ein primärer Wundverschluss (11,94%) 
durchgeführt. In meisten Fällen (53,73%) wurden zusätzliche Hämostyptika wie Gelatin 
oder Kollagen appliziert, bei ausgeprägten Nachblutungen nach Zahnextraktionen wur-
den Verbandsplatten (29,85%) angefertigt. Bei einem Großteil der Patienten (91,79%) 
wurde aufgrund einer intraoralen Nachblutung eine stationäre Aufnahme notwendig.  
 
Schlussfolgerungen: 
 Postoperative Nachblutung treten häufiger bei Patienten mit Herz- oder Gefäß-
erkrankungen aufgrund ihrer antikoagulatorischen Therapie auf. Zahnärzte sind 
zu einer detaillierten allgemeinen Anamnese mit Dokumentation der Medikation 
angehalten. 
 Bei der Entscheidung, antikoagulatorische Medikamente ab- oder umzusetzen, 
muss eine durch den Entzug der Medikation bedingte erhöhte Morbidität des Pa-
tienten (z.B. Embolie, Koronarstenose) mitberücksichtigt werden. Eine Rück-
sprache mit dem behandelnden Hausarzt ist diesbezüglich zu empfehlen.  
 Ein Absetzen der Medikation mit ASS ist vor Einzelzahnextraktionen nicht 
zwingend notwendig. Im Falle von Reihenextraktionen oder ausgedehnteren in-
vasiven Verfahren ist eine postoperative stationäre Überwachung sinnvoll. Eine 
Marcumartherapie (Phenprocoumon) kann bei Einzelzahnextraktionen fortge-
führt werden. Bei größeren Eingriffen mit erhöhtem Blutungsrisiko ist die Um-
stellung auf niedermolekulare Heparine indiziert. In allen Fällen ist eine statio-
näre Überwachung des Patienten zu empfehlen. 
 Patienten mit einer Hämophilie sollten unter stationären Bedingungen operiert 
werden. Vor Verabreichung eines Gerinnungsfaktors ist die Rücksprache mit 
dem behandelnden Hämatologen erforderlich. 
 Bei Patienten mit Lebererkrankung muss vor dem operativen Eingriff das Aus-
maß der Hepatopathie durch Rücksprache mit dem behandelnden Internisten 
bzw. Chirurgen sowie durch ein aktuelles Labor abgeklärt werden.  
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 Bezüglich der Lokalisation treten Nachblutungen nach Zahnextraktionen am 
häufigsten im Bereich des posterioren Oberkiefers, der Molarenregion auf.  
 Bezüglich des Zeitpunkts kommt es zumeist am ersten oder zweiten postoperati-
ven Tag zu Nachblutungen. Jedoch bleibt das Risiko einer postoperativen Nach-
blutung auch mehrere Tage nach der Operation bis zum Tag der Nahtentfernung 
bestehen. 
 Der dichte Wundverschluss der Alveole, gegebenenfalls durch eine plastische 
Deckung und der zusätzlichen Applikation eines Hämostyptikums, ist die 
sicherste Form der Blutstillung nach einer Zahnextraktion bei Patienten mit ei-
ner Gerinnungsstörung. Die Anfertigung einer Verbandsplatte ist besonderes bei 
rezidivierenden Blutungen oder ambulanten Operationen sinnvoll. 
 Patienten mit einer Parodontitis können unter laufender Antikoagulation nach 
einer professionellen Zahnreinigung und Kürettage bluten. In seltenen Fällen 
treten Blutungen bei diesen Patienten auch spontan auf. 
 Die Behandlung von Patienten mit Nachblutungen bedingt häufig eine stationäre 
Überwachung. Dabei können die Wundverhältnisse sowie die Laborparameter 
(Hämoglobin, Gerinnung, Elektrolyte) kontinuierlich kontrolliert werden, zudem 
sind notwendige Transfusion von Erythrozytenkonzentraten gewährleistet. 
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